Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS20080213331 A1
Type de publicationDemande
Numéro de demandeUS 12/099,638
Date de publication4 sept. 2008
Date de dépôt8 avr. 2008
Date de priorité8 avr. 2002
Autre référence de publicationUS9192715, US20140324016, US20160095862
Numéro de publication099638, 12099638, US 2008/0213331 A1, US 2008/213331 A1, US 20080213331 A1, US 20080213331A1, US 2008213331 A1, US 2008213331A1, US-A1-20080213331, US-A1-2008213331, US2008/0213331A1, US2008/213331A1, US20080213331 A1, US20080213331A1, US2008213331 A1, US2008213331A1
InventeursMark Gelfand, Howard R. Levin
Cessionnaire d'origineArdian, Inc.
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Methods and devices for renal nerve blocking
US 20080213331 A1
Résumé
A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluding implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.
Images(10)
Previous page
Next page
Revendications(117)
1-23. (canceled)
24. An implantable system for treating a patient diagnosed with at least one of heart failure, hypertension, acute myocardial infarction, renal disease, or chronic renal failure, the system comprising:
a drug delivery device having a proximal section and a distal section, wherein the distal section is configured to be at least partially implanted within a periarterial space of the patient;
an implantable drug pump operatively connected to the proximal section of the drug delivery device, wherein the implantable drug pump further includes a drug reservoir; and
a controller configured to operate instructions that cause the implantable drug pump to deliver via the drug delivery device a neuromodulatory agent to a nerve that innervates a kidney of the patient in an amount and for a duration sufficient to modulate at least one of urine production, blood pressure, fluid retention, renin secretion, renal blood flow, waste excretion, and sodium retention in the patient.
25. The implantable system of claim 24 wherein a nerve that innervates a kidney of the patient comprises an afferent nerve.
26. The implantable system of claim 24 wherein a nerve that innervates a kidney of the patient comprises an efferent nerve.
27. The implantable system of claim 24 wherein the drug delivery device comprises a catheter.
28. The implantable system of claim 27 wherein the catheter is configured for insertion into the patient such that the distal portion of the catheter at least partially encircles a renal blood vessel.
29. The implantable system of claim 28 wherein the distal portion of the catheter comprises a coil section.
30. The implantable system of claim 27 wherein the distal portion of the catheter comprises a flexible section.
31. The implantable system of claim 27 wherein the distal portion of the catheter further comprises a porous section.
32. The implantable system of claim 31 wherein the porous section is configured to receive an in-growth of tissue.
33. The implantable system of claim 31 wherein the porous section is configured to prevent an in-growth of tissue.
34. The implantable system of claim 31 wherein the porous section comprises pores with a dimension from approximately 1.0 μm to approximately 20.0 μm.
35. The implantable system of claim 31 wherein the porous section further comprises a large pore section having a first pore size and a small pore section having a second pore size less than the first pore size.
36. The implantable system of claim 35 wherein the first pore size is configured for receiving tissue in-growth and the second pore size is configured to prevent tissue in-growth.
37. The implantable system of claim 35 wherein the small pore section is configured to deliver the neuromodulatory agent to the nerve of the patient.
38. The implantable system of claim 35 wherein the first pore size is approximately 20 μm and the second pore size is approximately 1 μm.
39. The implantable system of claim 31 wherein the porous section comprises PTFE.
40. The implantable system of claim 27 wherein the distal section of the catheter comprises means for facilitating tissue ingrowth.
41. The implantable system of claim 27 wherein the distal section of the catheter comprises means for directional delivery of the neuromodulatory agent.
42. The implantable system of claim 27 wherein the distal section of the catheter comprises a Dacron cuff.
43. The implantable system of claim 27 wherein the catheter comprises a plurality of branches.
44. The implantable system of claim 43 wherein the catheter comprises a bifurcated catheter.
45. The implantable system of claim 44 wherein the bifurcated catheter is configured for bilateral placement.
46. The implantable system of claim 43 wherein the plurality of branches comprise a plurality of holes for delivering the neuromodulatory agent to the nerve of the patient.
47. The implantable system of claim 27 wherein the distal portion of the catheter comprises an end hole for delivery of the neuromodulatory agent.
48. The implantable system of claim 27 wherein the catheter is configured with at least one side port for delivery of the neuromodulatory agent.
49. The implantable system of claim 27 wherein the distal portion of the catheter further comprises means for delivering the nerve-blocking agent to the nerve of the patient.
50. The implantable system of claim 24 wherein the neuromodulatory agent is at least one anesthetic, neurotoxin, alcohol, phenol, ketamine and antidepressant.
51. The implantable system of claim 24 wherein the neuromodulatory agent is an anesthetic.
52. The implantable system of claim 51 wherein the anesthetic is amino ester, amino amide and/or bupivacaine.
53. The implantable system of claim 24 wherein the drug delivery device is further configured to deliver a medicament for suppressing inflammation in the periarterial space of the patient.
54. The implantable system of claim 53 wherein the medicament for suppressing inflammation in the periarterial space of the patient is a steroid.
55. The implantable system of claim 24, further comprising means for suppressing inflammation in the periarterial space of the patient.
56. The implantable system of claim 24 wherein the controller comprises a programmable microprocessor.
57. The implantable system of claim 56, further comprising a remote communication link for programming the programmable microprocessor.
58. The implantable system of claim 24 wherein the drug reservoir comprises a septum.
59. The implantable system of claim 58 wherein the septum comprises self-sealing means.
60. The implantable system of claim 24 wherein the implantable drug pump further comprises a displacement mechanism for forcing the neuromodulatory agent from the drug reservoir to the drug delivery device.
61. The implantable system of claim 60 wherein the displacement mechanism comprises an elastic diaphragm.
62. The implantable system of claim 61 wherein the displacement mechanism further comprises a propellant.
63. The implantable system of claim 24 wherein the implantable drug pump further comprises means for displacing the neuromodulatory agent from the drug reservoir to the drug delivery device.
64. The implantable system of claim 24, further comprising a rate limiting element for controlling the delivery rate of the neuromodulatory agent.
65. The implantable system of claim 24 wherein the distal section of the drug delivery device comprises an electrode.
66. An apparatus for treating a patient diagnosed with at least one of heart failure, hypertension, acute myocardial infarction, renal disease, or chronic renal failure, the apparatus comprising:
an implantable catheter having a proximal section and a distal section, wherein the distal section is configured to be at least partially positioned within a periarterial space of the patient; and
a subcutaneous injection port operatively connected to the proximal section of the implantable catheter,
wherein the subcutaneous injection port is configured to receive an injection of a neuromodulatory agent and supply the neuromodulatory agent via the implantable catheter to a nerve that innervates a kidney of the patient in an amount and for a duration sufficient to modulate at least one of urine production, blood pressure, fluid retention, renin secretion, renal blood flow, waste excretion, and sodium retention in the patient.
67. The apparatus of claim 66 wherein a nerve that innervates a kidney of the patient further comprises an afferent nerve.
68. The apparatus of claim 66 wherein a nerve that innervates a kidney of the patent further comprises an efferent nerve.
69. The apparatus of claim 66, further comprising an external drug pump operatively and detachably connected to the subcutaneous injection port.
70. The apparatus of claim 66 wherein the subcutaneous injection port is configured to receive an injection of a neuromodulatory agent from a needle.
71. The apparatus of claim 66 wherein the subcutaneous injection port is configured to receive an injection of a neuromodulatory agent from a gravity feed.
72. The apparatus of claim 66 wherein the subcutaneous injection port is configured to receive an injection of a neuromodulatory agent from an external pump.
73. The apparatus of claim 66 wherein the catheter is configured for insertion into the patient such that the distal portion of the catheter at least partially encircles a renal blood vessel.
74. The apparatus of claim 73 wherein the distal portion of the catheter comprises a coil section.
75. The apparatus of claim 66 wherein the distal portion of the catheter comprises a flexible section.
76. The apparatus of claim 66 wherein the distal portion of the catheter further comprises a porous section.
77. The apparatus of claim 76 wherein the porous section is configured to receive an in-growth of tissue.
78. The apparatus of claim 76 wherein the porous section is configured to prevent an in-growth of tissue.
79. The apparatus of claim 76 wherein the porous section comprises pores with a dimension from approximately 1.0 μm to approximately 20.0 μm.
80. The apparatus of claim 76 wherein the porous section comprises PTFE.
81. The apparatus of claim 76 wherein the porous section further comprises a large pore section having a first pore size and a small pore section having a second pore size less than the first pore size.
82. The apparatus of claim 81 wherein the first pore size is configured for receiving tissue in-growth and the second pore size is configured to prevent tissue in-growth.
83. The apparatus of claim 81 wherein the small pore section is configured to deliver the neuromodulatory agent to the nerve of the patient.
84. The apparatus of claim 81 wherein the first pore size is approximately 20 μm and the second pore size is approximately 1 μm.
85. The apparatus of claim 66 wherein the distal section of the catheter comprises means for facilitating tissue ingrowth.
86. The apparatus of claim 66 wherein the distal section of the catheter comprises means for directional delivery of the neuromodulatory agent.
87. The apparatus of claim 66 wherein the distal section of the catheter comprises a Dacron cuff.
88. The apparatus of claim 66 wherein the catheter comprises a plurality of branches.
89. The apparatus of claim 88 wherein the catheter comprises a bifurcated catheter.
90. The apparatus of claim 89 wherein the bifurcated catheter is configured for bilateral placement.
91. The apparatus of claim 88 wherein the plurality of branches comprise a plurality of holes for delivering the neuromodulatory agent to the nerve of the patient.
92. The apparatus of claim 69 wherein the distal portion of the catheter comprises an end hole for delivery of the neuromodulatory agent.
93. The implantable system of claim 69 wherein the catheter is configured with at least one side port for delivery of the neuromodulatory agent.
94. An apparatus for treating a patient diagnosed with at least one of heart failure, hypertension, acute myocardial infarction, renal disease, or chronic renal failure, the apparatus comprising:
a drug delivery device configured to be at least partially positioned in a periarterial space of the patient;
an electrode configured to be positioned proximate to a nerve that innervates a kidney of the patient; and
an energy generator operatively coupled to at least one of the drug delivery device and the electrode.
95. The apparatus of claim 94 wherein the energy generator is operatively connected to the electrode and comprises a controller containing instructions configured to cause the electrode to deliver electrical signals to the nerve.
96. The apparatus of claim 94, further comprising a controller containing instructions configured to cause the drug delivery device to inhibit neural activity along the nerve for a period of time sufficient to modulate at least one urine production, blood pressure, fluid retention, renin secretion, renal blood flow, waste excretion, and sodium retention in the patient.
97. The apparatus of claim 94 wherein the drug delivery device comprises a catheter configured for insertion in the patient such that a distal portion of the catheter extends within the periarterial space.
98. The apparatus of claim 97 wherein the distal portion of the catheter has a plurality of holes through which a nerve-blocking agent can be delivered to a renal nerve of the patient.
99. The apparatus of claim 97 wherein the distal portion of the catheter comprises a porous section having pores through which a nerve-blocking agent can be delivered to a renal nerve of the patient.
100. The apparatus of claim 99 wherein the porous section has pores with a dimension of from approximately 1.0 μm to 20.0 μm.
101. The apparatus of claim 99 wherein the porous section has a large pore section having a first pore size and a small pore section having a second pore size less than the first pore size.
102. The apparatus of claim 101 wherein the first pore size is configured for tissue in-growth and the second pore size is configured to prevent tissue in-growth.
103. The apparatus of claim 101 wherein the first pore size is approximately 20 μm and the second pore size is approximately 1 μm.
104. The apparatus of claim 97 wherein the electrode is coupled to the distal portion of the catheter.
105. The apparatus of claim 97 wherein the electrode comprises a first electrode configured to be located proximally of a nerve modulating site and a second electrode configured to be located distally of the nerve modulating site.
106. The apparatus of claim 105 wherein at least one of the first and second electrodes comprises a sensor that senses neural activity.
107. The apparatus of claim 105 wherein the first and second electrodes comprise contacts configured to apply stimulation to a renal nerve of the patient.
108. The apparatus of claim 97 wherein the distal portion of the catheter comprises a flexible section configured to at least partially wrap around a portion of a renal vessel of the patient.
109. The apparatus of claim 108 wherein the flexible section further comprises at least one of a coil, a plurality of openings and a porous section.
110. The apparatus of claim 94 wherein the drug delivery device comprise a drug-eluting implant.
111. The apparatus of claim 110 wherein the drug-eluting implant is configured to at least partially wrap around at least a portion of a renal vessel of the patient.
112. The apparatus of claim 94 wherein the drug delivery device comprises a sustained release, bio-degradable implant having a nerve-blocking agent.
113. The apparatus of claim 112 wherein the sustained release, bio-degradable implant comprises at least one of a patch, a plurality of micro-particles, a plurality of micro-spheres, and a plurality of micro-capsules.
114. The apparatus of claim 95 wherein the instructions are further configured to cause the controller to determine via the electrode whether neural activity along the renal nerve has been substantially blocked.
115. The apparatus of claim 96 wherein the energy generator is also operatively coupled to the electrode and the instructions are further configured to cause the controller to determine via the electrode whether neural activity along the nerve has been sufficiently altered.
116. The apparatus of claim 114 wherein the instructions are further configured to cause the drug delivery device to inhibit neural activity along the nerve based on whether neural activity along the renal nerve has been substantially blocked.
117. The apparatus of claim 114 wherein the instructions are further configured to cause the controller to electrically stimulate the renal nerve and cause a response in the patient.
118. The apparatus of claim 117 wherein the instructions are further configured to adjust the drug delivery based on the response caused in the patient.
119. The apparatus of claim 117 wherein an operator adjusts the drug delivery based on the response caused in the patient.
120. An apparatus for at least partially blocking a renal nerve of a kidney of a human patient, the apparatus comprising:
a drug eluting device configured for placement in a periarterial space of the patient,
wherein the drug eluting device is loaded with a diffusible supply of a nerve-blocking drug for delivery to the periarterial space in an amount and for a duration sufficient to modulate at least one of urine production, blood pressure, fluid retention, renin secretion, renal blood flow, waste excretion, and sodium retention in the patient.
121. The apparatus of claim 120 wherein the drug eluting device comprises a biodegradable polymeric matrix.
122. The apparatus of claim 120 where the nerve-blocking drug is selected from the group consisting of an anesthetic, alcohol, phenol, ketamine, neurotoxin, and antidepressant.
123. The apparatus of claim 120 wherein the drug eluting device comprises a biodegradable gel.
124. The apparatus of claim 120 wherein the drug eluting device comprises a drug-impregnated matrix.
125. The apparatus of claim 124 wherein the drug-impregnated matrix comprises a gel, patch, microspheres, suspension and/or solution.
126. The apparatus of claim 120 wherein the drug eluting device is configured to at least partially surround a renal blood vessel.
127. The apparatus of claim 120 wherein the drug eluting device comprises an osmotic pump.
128. The apparatus of claim 120 wherein the drug eluting device comprises a biodegradable compound.
129. The apparatus of claim 128 wherein the biodegradable compound is selected from the group consisting of a polyanhydride, polyester excipient, acid-glycolic acid copolymer and polycaprolactone.
130. The apparatus of claim 120 wherein the nerve-blocking drug is combined with a steroid.
131. The apparatus of claim 130 wherein the steroid comprises glucocorticoid.
132. An apparatus for treating a patient diagnosed with at least one of heart failure, hypertension, acute myocardial infarction, renal disease, or chronic renal failure, the apparatus comprising:
a first drug delivery device configured to be positioned proximate to a first nerve that innervates a first kidney of the patient; and
a second drug delivery device configured to be positioned proximate to a second nerve that innervates a second kidney of the patient,
wherein the first drug delivery device is configured to deliver a nerve-blocking agent to the first nerve that innervates the first kidney and inhibit neural activity along the first nerve, and the second drug delivery device is configured to deliver the nerve-blocking agent to the second nerve that innervates the second kidney and inhibit neural activity along the second nerve, and wherein the nerve-blocking agent is delivered by the first and second drug delivery devices in an amount and for a period of time sufficient to modulate at least one urine production, blood pressure, fluid retention, renin secretion, renal blood flow, waste excretion, and sodium retention in the patient.
133. The apparatus of claim 132 wherein at least one of the first drug delivery device and the second drug delivery device is a drug eluting implant.
134. The apparatus of claim 132 wherein at least one of the first drug delivery device and the second drug delivery device is a catheter.
135. The apparatus of claim 132, further comprising a drug reservoir operatively connected to the first drug delivery device and the second drug delivery device, and wherein the drug reservoir delivers the nerve-blocking agent to the first drug delivery device and the second drug delivery device.
136. The apparatus of claim 135 wherein the drug reservoir is configured to concurrently deliver the nerve-blocking agent to the first drug delivery device and the second drug delivery device.
137. The apparatus of claim 135 wherein the drug reservoir is configured to sequentially deliver the nerve-blocking agent to the first drug delivery device and the second drug delivery device.
138. The apparatus of claim 135 wherein the drug reservoir comprises an implantable drug pump.
139. The apparatus of claim 135 wherein the drug reservoir comprises an external drug reservoir.
Description
    RELATED APPLICATIONS
  • [0001]
    This application is related and claims priority to the following commonly-owned applications, Ser. No. 60/408,665, entitled “Renal Nerve Stimulation Method And Apparatus For Treatment Of Patients” that was filed in the U.S. Patent and Trademark Office (USPTO) on Apr. 8, 2003 and provisional applications Ser. No. 60/370,190, entitled “Modulation Of Renal Nerve To Treat CHF”, that was filed in the U.S. Patent and Trademark Office (USPTO) on Apr. 8, 2002; Ser. No. 60/415,575 entitled “Modulation Of Renal Nerve To Treat CHF”, that was filed in the USPTO on Oct. 3, 2002, and Ser. No. 60/442,970 entitled “Treatment Of Renal Failure And Hypertension”, that was filed in the USPTO on Jan. 29, 2003. The entirety of each of these applications is incorporated by reference herein.
  • FIELD OF THE INVENTION
  • [0002]
    This invention relates to devices and methods for local drug delivery, and in particular is directed to an implantable system for targeted delivery of a nerve blocking agent to the periarterial space of the renal artery for the purpose of blocking the renal nerve plexus, methods for implanting same, and methods and devices for treating diseases. The invention directs the nerve-blocking agent towards the nerve, prevents dissipation of the agent in the surrounding tissue and provides fixation of the drug delivery mechanism in the surrounding tissue.
  • BACKGROUND OF THE INVENTION
  • [0003]
    Hypertension (HTN) and congestive heart failure (CHF) are the most important problems in contemporary cardiology. These chronic diseases account for most cardiovascular morbidity and mortality, and, despite much progress, remain therapeutic challenges. The cornerstone of therapy for both HTN and CHF includes the use primarily oral and intravenous drugs acting directly or indirectly on the kidney, such as angiotensin converting enzyme (ACE) inhibitors and diuretics, with the amount of each drug used dependent on the stage of the disease. While drug therapy is effective in the earliest stages of HTN and CHF, there is no truly effective drug treatment for the mid-to-later stages of these diseases.
  • [0004]
    HTN and CHF have many different initial causes. Irrespective of initial cause, both diseases follow a common pathway in their progression to end-stage disease, primarily as the result of excessive activity of the renal nerve. It has been shown in accepted animal models that renal denervation can control HTN and improve symptoms and slow down the progression of CHF. However, no drug or device therapies currently exist that can provide long-term, clinically usable blocking of renal nerve activity in humans. The only available clinical method of renal denervation is an invasive surgical procedure, technically difficult and of limited use, as the nerve quickly regenerates.
  • [0005]
    Of particular significance for this invention is the CHF condition that develops in many patients following a myocardial infarction (MI). Coronary artery disease causes approximately 70% of congestive heart failure. Acute MI due to obstruction of a coronary artery is a common initiating event that can lead ultimately to heart failure. This process by which this occurs is referred to as remodeling and is described in the text Heart Disease, 5th ed., E. Braunwald, Ch. 37 (1997). Remodeling after a myocardial infarction involves two distinct types of physical changes to the size, shape and thickness of the left ventricle. The first, known as infarct expansion, involves a localized thinning and stretching of the myocardium in the infarct zone. This myocardium can go through progressive phases of functional impairment, depending on the severity of the infarction. These phases reflect the underlying myocardial wall motion abnormality and include an initial dyssynchrony, followed by hypokinesis, akinesis, and finally, in cases that result in left ventricular aneurysm, dyskinesis. This dyskinesis has been described as “paradoxical” motion because the infarct zone bulges outward during systole while the rest of the left ventricle contracts inward. Consequently, end-systolic volume in dyskinetic hearts increases relative to nondyskinetic hearts.
  • [0006]
    The second physical characteristic of a remodeling left ventricle is the attempted compensation of noninfarcted region of myocardium for the infarcted region by becoming hyperkinetic and expanding acutely, causing the left ventricle to assume a more spherical shape. This helps to preserve stroke volume after an infarction. These changes increase wall stress in the myocardium of the left ventricle. It is thought that wall tension is one of the most important parameters that stimulate left ventricular remodeling. In response to increased wall tension or stress, further ventricular dilatation ensues. Thus, a vicious cycle can result, in which dilatation leads to further dilatation and greater functional impairment. On a cellular level, unfavorable adaptations occur as well. This further compounds the functional deterioration.
  • [0007]
    Takashi Nozawa et al reported the effects of renal denervation in “Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats” published in Heart Vessels (2002) 16:51-56 Springer-Verlag. In rats the bilateral renal nerves were surgically denervated (cut) (RD) two days before MI was induced by coronary artery legation. Four weeks later, left ventricular (LV) function and sodium excretion were determined. In MI rats, RD improved the reduced sodium excretion. MI RD rats revealed lower LV end-diastolic pressure and greater maximum dP/dt as compared with those of MI innervation (INN) rats. LV end-diastolic and end-systolic dimensions were significantly smaller and LV fractional shortening was greater in MI RD rats than in MI INN rats.
  • [0008]
    Inventors described novel methods and devices for reversible minimally invasive modulation of the renal nerve in copending applications. This application describes novel drug delivery methods and integrated physiological drug delivery and sensing systems that provide a significantly more effective method of blocking the renal nerve for the purpose of treating HTN and CHF than are currently available. The objective of this invention is a fully implantable device that blocks renal nerve activity of at least one kidney that 1) can be placed in a minimally invasive manner and 2) requires minimal intervention by the patient and physician; and will greatly increase patient compliance leading to a higher overall effectiveness of these therapies. In addition, to HTN and CHF, this method may be applicable to other major diseases such as slowing the progression of chronic renal failure and reducing the number of patients requiring chronic hemodialysis.
  • [0009]
    Nerve blocking in humans is known and practiced mostly in the field of local anesthesia and pain control. While compounds utilized as general anesthetics reduce pain by producing a loss of consciousness, local anesthetics act via a loss of sensation in the localized area of administration in the body. The mechanism by which local anesthetics induce their effect, while not having been determined definitively, is generally thought to be based upon the ability to locally interfere with the initiation and transmission of a nerve impulse, e.g., interfering with the initiation and/or propagation of a depolarization wave in a localized area of nerve tissue. The actions of local anesthetics are general, and any tissue where nerve conduction, e.g., cell membrane depolarization occurs can be affected by these drugs. Thus, nervous tissue mediating both sensory and motor functions can be similarly affected by local anesthetics. Neurotoxins are the chemicals that when applied to nerve tissue in extremely small amounts can block a nerve for a period of time that significantly exceeds that achieved with local anesthetics. They are also more toxic and potentially more dangerous to the patient than local anesthetics.
  • [0010]
    Different devices and formulations are known in the art for administration of local anesthetics. For example, local anesthetics can be delivered in solution or suspension by means of injection, infusion, infiltration, irrigation, topically and the like. Injection or infusion can be carried out acutely, or if prolonged local effects are desired, localized anesthetic agents can be administered continuously by means of a gravity drip or infusion pump. Thus, local anesthetics such as bupivacaine have been administered by continuous infusion, e.g., for prolonged epidural or intrathecal (spinal) administration. For prolonged control of pain fully implantable pumps have been proposed and implemented. These pumps can store a certain amount of drug and a physician periodically refills those. Several authors proposed drug eluding implants for control of pain and muscle spasms that slowly release an anesthetic agent at the site of implantation.
  • [0011]
    The duration of action of a local anesthetic is proportional to the time during which it is in actual contact with the nervous tissues. Consequently, procedures or formulations that maintain localization of the drug at the nerve greatly prolong anesthesia. Local anesthetics are potentially toxic, both locally and via systemic absorption, yet must be present long enough to allow sufficient time for the localized pain to subside. Therefore, it is of great importance that factors such as the choice of drug, concentration of drug, and rate and site of administration of drug be taken into consideration when contemplating their use for the application to block renal nerve. Charles Berde in “Mechanisms of Local Anesthetics” (Anesthesia, 5th addition, R. D. Miller, editor, Churchill-Livingstone, Philadelphia 2000, pp. 491-521) stipulated that only 1-2% of the total amount of local anesthetic, when delivered by traditional methods, ever reaches the nerve. The rest of the drug is dissipated by circulation of blood that takes the drug away, not towards the nerve. It is therefore the purpose of this invention to maximize the amount of drug directed towards the nerve so as to achieve the effective blockade of the renal nerve with the minimal amount of drug.
  • [0012]
    Theoretically, a suitable commercially available implantable drug pump such as a Syncromed pump made by Medtronic Inc. (Shoreview, Minn.) can be used to block the renal nerve in a human. The pump can deliver common commercially available solution of a local anesthetic agent such as bupivacaine to the tissue surrounding the renal nerve via an attached catheter. Although feasible, such embodiment of the renal nerve block will have practical limitations. To block a peripheral nerve (for example, for the purpose of a commonly performed brachial plexus block) using conventional techniques the physician typically infiltrates 10-50 ml of bupivacaine or similar anesthetic into the tissue surrounding the targeted nerve. This usually achieves adequate blocking of both sensory and motor signals for 2 to 6 hours. Commercially available bupivacaine marketed as Marcaine or Sensorcaine is available in concentrations of 0.25 to 0.1%. For peripheral (single nerve) blocks concentrations of 0.5 to 0.75% are typically used. There are several reasons why local anesthetics are so diluted. An amino-amide compound such as bupivacaine can be toxic both locally (it is an irritant) and systemically (it depresses the heart). It is generally perceived that a local anesthetic will not be effective below certain minimum concentration and will be toxic above certain maximum concentration.
  • [0013]
    Implantable drug pumps are commonly equipped with an internal drug storage reservoir of 30 to 50 ml. Bigger reservoirs are possible but impose severe limitations on the physical and clinical acceptability of the implant. If the continuous (24 hour a day 7 days a week) block of the patient's renal nerve is desired, and a conventional peripheral nerve blocking technique is used, the implanted pump reservoir will need to be refilled every day or even more frequently. This is possible but not practical, since refilling of the pump is associated with the skin puncture, causing pain and leading to the risk of local and systemic infection. Also, daily infusion of a large amount of drug can result in a serious risk to the patient's health, especially if the patient has a weak heart. Notably the same drug bupivacaine is effective in a much lower doze when delivered directly to the targeted nerve tissue in the patient's spine. For example, an effective intrathecal (spinal) pain block can be achieved with 2-5 ml of bupivacaine. This observation shows that more targeted delivery of the same drug to the nerve tissue can result in 10 times or more reduction of the amount of drug needed for nerve blocking.
  • [0014]
    It is therefore the purpose of this invention to provide novel methods and implantable devices that will effectively block renal nerve by targeting the delivery of the selected drug to the nerve, reducing dissipation of the drug into the surrounding tissue, reducing the amount of drug stored in the device and increasing the time interval between the refilling or replacement of the device. It is also the purpose of this invention to enable testing of the effectiveness of the renal nerve blockade and to perform the renal block automatically, intermittently and/or periodically in the clinical scenarios where the continuous block is not desired.
  • SUMMARY OF THE INVENTION
  • [0015]
    Surgical denervation of the kidney in experimental animals suggested multiple immediate and long-term benefits for patients with cardiac and renal diseases. The most significant potential beneficial effects are: slowing of the progression of CHF, resolution of fluid overload in CHF by induction or enhancement of diuresis, reduction of remodeling after a myocardial infarct, reduction of hypertension and slowing of the progression of chronic renal disease to dialysis. The benefits are achieved via the reduction of the systemic sympathetic tone causing vasoconstriction of blood vessels, reduction of the load on the heart and the direct effects of denervation on the kidney. Both single kidney denervation and bilateral denervation have potential benefits. Surgical denervation has been previously performed in animals and in few humans to control pain. It requires a major surgery and is ineffective in long term, since renal nerves eventually grow back. Additionally, after the surgical denervation, the renal nerve can re-grow in a pathological way and can cause pain and other serious side effects. Since fibrotic changes at the site of denervation make repeat surgical denervation impossible, patients face the possibility of the removal of the kidney to control the pain.
  • [0016]
    The inventors suggest an alternative method of reducing or blocking the renal nerve activity in patients by minimally invasive renal nerve modulation. Renal nerve modulation is achieved by controlled infusion of a nerve-blocking agent into the periarterial space of the renal artery of the kidney. The periarterial space is the area surrounding the renal arteries and veins, extending from the aorta and vena cava to and including the area around the kidney itself. Since renal nerves follow the external surface of the renal artery, when an effective concentration of the nerve-blocking agent is present in this periarterial space, the renal nerve activity is substantially reduced or stopped. Methods and devices for both continuous and intermittent periodic blocking of the renal nerve are proposed. These methods and devices provide effective, reversible nerve blocking for a clinically relevant duration of time, while avoiding major surgery and irreparable damage to the nerve that characterize the previously used surgical denervation.
  • [0017]
    The preferred embodiment devices can be implantable drug pumps or drug eluding implants. Both classes of local drug delivery devices are known. Implanted pumps have been successfully-used previously for control of pain by infusion of local anesthetics into the patient's spine. Implantable pumps range from simple reservoirs (ports) implanted under the skin with an attached catheter to sophisticated microprocessor driven programmable devices similar to pacemakers. Drug eluding implants have been used to deliver birth control agents and to prevent restenosis of coronary arteries.
  • [0018]
    Implanted pumps can also be refilled with drug without surgery using a transdermal port accessible with a needle, though it is preferable to extend the time between refillings to minimize pain and the risk of infection. The programmable implantable pump embodiment also has an advantage of the periodic drug delivery that can be adjusted up or down using a remote communication link. This is particularly significant in treatment of chronic diseases such as CHF where the continuous constant nerve blocking can result in adaptation (resting of the physiologic gain or compensation) and the loss of therapeutic effect.
  • [0019]
    Drug eluding implants work primarily by diffusion. Drug eluding implants are advantageous in the treatment of a temporary condition such as infarct expansion following acute MI where an implant that blocks the nerve for approximately 30 days and then dissolves on its own can be the best embodiment of the invention.
  • SUMMARY OF THE DRAWINGS
  • [0020]
    A preferred embodiment and best mode of the invention is illustrated in the attached drawings that are described as follows:
  • [0021]
    FIG. 1 illustrates the patient treated with an implanted pump embodiment of the invention.
  • [0022]
    FIG. 2 illustrates the physiologic mechanisms of renal nerve modulation.
  • [0023]
    FIG. 3 illustrates anatomic positioning of the renal nerve blocking device.
  • [0024]
    FIG. 4 illustrates an implantable drug infusion pump with a catheter electrode.
  • [0025]
    FIG. 5 illustrates the infusion of an anesthetic drug into the renal fatpad.
  • [0026]
    FIG. 6 illustrates a catheter with a cuff for distributed drug infusion into the periarterial space.
  • [0027]
    FIG. 7 illustrates a bifurcated catheter for drug infusion into the periarterial space.
  • [0028]
    FIG. 8 illustrates a coiled catheter for drug infusion into the periarterial space.
  • [0029]
    FIG. 9 illustrates a drug eluding implant in the periarterial space.
  • [0030]
    FIG. 9A illustrates a drug eluding biodegradable material in the periarterial space.
  • [0031]
    FIG. 10 illustrates a porous drug infusion catheter.
  • [0032]
    FIG. 11 illustrates a drug infusion catheter with tissue ingrowth.
  • [0033]
    FIG. 12 illustrates the drug infusion catheter that directs the drug towards the renal nerve.
  • [0034]
    FIG. 13 illustrates the drug infusion catheter that overlaps the renal artery and directs the drug infusion towards the renal nerve.
  • [0035]
    FIG. 14 is a cross-sectional view of the catheter and artery shown in FIG. 13.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0036]
    For the proposed clinical use, the capability of the invention is to block the sympathetic activity of the renal nerve of the kidney by controlled local delivery of a nerve-blocking agent with the goal of improving the patient's renal and cardiac function. Elements of the invention are useful for blocking nerves for the purpose other than treating cardiorenal disease and can be applied in other anatomic locations.
  • [0037]
    A nerve blocking agent is a drug that reduces or blocks conduction of signals by renal nerves. The nerve blocking agents used can be selected from different groups including (1) local anesthetics, (2) ketamine (a well known sedative with nerve blocking properties), (3) tricyclic antidepressants such as amitriptyline, (4) neurotoxins such as tetrodotoxin and saxitoxin or (5) any other class or type of agent that transiently or permanently, partially or completely alters nerve conduction. The terms nerve blocking agent and nerve blocking drug are interchangeable.
  • [0038]
    Cardiorenal disease is defined as a condition, chronic or acute, that involves both the heart and the kidney. Examples of cardiorenal diseases are hypertension and CHF. Cardiorenal diseases are characterized by the elevated activity of the renal nerve.
  • [0039]
    For the purpose of this invention, the renal nerve is defined as a any individual nerve or plexus of nerves and ganglia that conducts a nerve signal to and/or from the kidney and is anatomically located on the surface of the renal artery, parts of aorta where the renal artery branches from the aorta and/or on branches of the renal artery. The renal nerve generally enters the kidney in the area of the hilum of the kidney, but may enter in any location where a renal artery or branch of the renal artery enters the kidney.
  • [0040]
    Periarterial space is defined as the space immediately surrounding the renal arteries, renal veins and their branches between the aorta and the hilum of the kidney. The renal fat pad is defined as the adipose tissue or fat that fills the periarterial space and surrounds the renal artery, renal vein, renal nerves and the kidney itself. The renal fascia is the layer of connective tissue that surrounds, envelopes and contains the renal artery, renal vein, renal fatpad and the kidney itself.
  • [0041]
    An implantable or implanted device (commonly termed an “implant”) is an artificial device fully enclosed in the patient's body. It is significant that implants allow the natural skin of the patient to serve as a barrier against infection. An implant can be, for example, a complex electromechanical pump, catheter and port or a drug-releasing polymer. Implantation can be achieved by open surgery, minimally invasive surgery or a transcatheter intervention, whether extravascular, intravascular or combination of any of the above. During the implantation procedure, a surgical instrument or catheter is used to cross the skin, penetrating into the patient's body. The implant is positioned at the desired site and the pathway used to access the site is closed. The site heals and the device is now fully implanted.
  • [0042]
    An implantable pump is an implantable device that is inserted under the patient's skin and can be refilled using a transdermal needle access. An implantable pump may have an integral catheter or can be equipped with a separate catheter that delivers medication to the periarterial space. Depending on the desired treatment modality, a preferred implantable pump can be programmable, patient controlled or a constant rate device.
  • [0043]
    A drug eluding implant is a device that is fully implanted in the body that slowly eludes the nerve-blocking agent into the target space. One example of such a space is the renal periarterial space. Another example is inside the renal capsule, or the virtual space between the kidney tissue and the fibrous sheath surrounding the kidney tissues itself. Drug eluding implants work by diffusion and can be biodegradable or not. An osmotic pump is also a drug eluding implant. Different matrixes that serve to slow down the diffusion of the drug into a target space are all called drug eluding implants for the purpose of this invention. These include gels, patches, injectable microspheres, suspensions, solutions or any other matrix that may hold sufficient drug to cause the intended effect.
  • [0044]
    FIG. 1 illustrates a patient 101 treated with the preferred embodiment of the invention. Patient has kidneys 103 and 104 that are bean shaped organs 12 cm long, 6 cm wide, 3 cm thick located outside and behind the peritoneal cavity. Patient is equipped with an implantable drug pump 105 implanted in the patient's side under the skin. The pump is equipped with a drug delivery catheter 106 that terminates in the area of the renal artery 107 where the delivered drug is capable of blocking the renal nerve.
  • [0045]
    FIG. 2 illustrates the role of renal nerve activity in the progression of chronic cardiac and renal diseases. Increased renal afferent (from the kidney to the brain) nerve activity 201 results in the increased systemic sympathetic tone 202 and vasoconstriction (narrowing) 203 of blood vessels. Increased resistance of blood vessels results in hypertension 204. Hypertension is a major contributor to the progression of chronic heart failure and renal failure as well as the acute events such as strokes and myocardial infarcts. Increased renal efferent (from the brain to the kidney) nerve activity 205 results in further increased afferent renal nerve activity, secretion of the renal hormone renin 206, and reduction of renal blood flow and the decreased water and sodium excretion by the kidney. Renin contributes to systemic vasoconstriction of blood vessels 203. In combination these renal factors result in fluid retention 207 and increased workload of the heart thus contributing to the further deterioration of the patient. It should be clear from the FIG. 2 that moderation of renal nerve activity will benefit patients with heart, kidney and circulatory system (cardiorenal) diseases.
  • [0046]
    FIG. 3 illustrates a preferred embodiment of the invention using a CT scan (digital X-ray) image of a human body. The pump 105 is implanted under the skin in the patient's back. The pump is equipped with the catheter 106. Tip 304 of the catheter resides near the renal artery 107. In this example, the tip 304 is shown in the hilum 305 area of the kidney where the renal blood vessels (arteries and veins) enter and exit the kidney. In clinical practice, the tip could reside in other locations within the renal periarterial space as long as the position allows the spread of the nerve blocking agent to at least a sufficient area of the nerve to achieve the required level of nerve blockade. Each kidney has an outer convex surface and an indentation on the inner side called the hilum. The hilum functions as a route of entry and exit for the blood vessels, lymph vessels, nerves and ureters of the kidney. Renal nerves follow the renal artery 107 that connects the kidney 104 to the aorta 301 shown in front of the spine 302. Kidney and renal vessels are enclosed in fat and fascia made of connective tissues that do not show well on this type of CT scan image.
  • [0047]
    It is significant that the catheter 106 can be introduced into the periarterial space under the CT guidance without surgery. The spatial resolution of modern imaging modalities such as CT, CT Fluoroscopy, Ultrasound and MRI allows an interventional radiologist to position the catheter within a millimeter from the renal artery of a human. The procedure is performed using a needle, an exchange guidewire and similar techniques commonly used in interventional radiology. The distal end of the catheter can be left outside of the body for the test period or the entire treatment if the treatment requires only a short duration. Later, if the renal nerve blocking therapy is clinically successful, an implanted pump or a simple subcutaneous port such as a commercially available Port-A-Cath device can be connected to the already implanted catheter for repeat infusions of the nerve-blocking drug.
  • [0048]
    FIG. 4 illustrates a simplified design of an implantable programmable drug infusion pump. The pump 105 in implanted in a pocket under the patient's skin 401. All the mechanisms of the pump are enclosed in a titanium or polymer case 402. Drug is stored in the reservoir 403. To refill the pump a needle 405 is used to puncture the skin and the pump reservoir septum 406. Septum 406 is made of a material such as silicon that seals after the puncture. Drug is displaced from the reservoir by the compressed propellant 407. The propellant can be a chlorofluorocarbon, butane or other similar compound. The propellant acts on the drug through the elastic diaphragm 408. Alternatively, the diaphragm can act as a spring or it can be acted upon by the spring to displace the drug. The catheter 106 is in fluid communication with the reservoir 403. The propellant urges the drug from the reservoir into the catheter and through the catheter to the site of delivery, in this case, periarterial space of the renal artery and the renal nerve. To control the release of the drug, a valve 408 is placed between the reservoir and the catheter. The valve is normally closed. When it is forced open by the pump electronic control circuitry 409 for a short duration of time, a bolus of drug is released from the pump to the renal nerve-blocking site. The internal battery 411 supplies energy to the electronics and the valve. The communication electronics 410 allows the physician to reprogram the pump altering the amount and frequency of drug delivery as well as to interrogate the device. The communication electronics can be a radio-frequency RF link. All the elements described above are known to the developers of implantable drug pumps.
  • [0049]
    Programmable implantable infusion devices (also called implantable pumps) that actively meter the drug into an associated drug delivery catheter are described in the U.S. Pat. Nos. 4,692,147; 5,713,847; 5,711,326; 5,458,631; 4,360,019; 4,487,603; and 4,715,852. Alternatively, implantable infusion devices can control drug delivery by means of a rate-limiting element positioned between the drug reservoir and the delivery catheter as described in the U.S. Pat. No. 5,836,935, or by only releasing drug from the reservoir upon application of pressure to a subcutaneously positioned control device as described in U.S. Pat. Nos. 4,816,016 and 4,405,305. Implantable infusion devices have been used for intravenous, intraarterial, intrathecal, intraperitoneal, intraspinal and epidural drug delivery but not for periarterial drug infusion.
  • [0050]
    Known infusion pumps described above can be used to block the renal nerve for the purpose of treating cardiac diseases but they lack certain features needed in practical application. It is important for the physician to be able to determine that the nerve is in fact effectively blocked. In pain control applications of local anesthetics, the disappearance of the pain by itself is an indicator of an effective block. There is no natural indication of the renal nerve activity that can be simply measured. To address that problem, the pump 105 is equipped with a test electrode 412 on the tip 304 of the catheter 106. The electrode can be a single ring or multiple electrodes made of a conductive metal such as gold, stainless steel or titanium. The electrode 412 is connected to the control circuitry of the pump 409 by a conductive wire 413 integrated inside the catheter body 106. Except for the tip electrode 412 the wire is electrically insulated from the patient.
  • [0051]
    To test the effectiveness of the renal nerve block the control circuitry initiates an electric pulse to the electrode. To close the electric circuit the metal case 402 of the pump can be used as a second return electrode. Alternatively the catheter 106 can be equipped with more than one electrode. Low electric current pulse that can be in the range of 5-10 milliamps is passed through the tissue surrounding the electrode 412. If the nerve block is effective, patient will have no sensation of tingling or minor electric shock. If the block is ineffective, the nerves in the surrounding tissue will conduct the pulse, causing pain that the patient then reports to the physician and the physician will be able to make adjustments to therapy such as, for example, increase the dose of drug delivered by the pump.
  • [0052]
    This aspect is similar to the surgical technique used by anesthesiologists to establish short term invasive nerve blocks during surgery. Before the start of the surgery, the anesthesiologist places a needle precisely on the nerve or plexus. To do this, a specially designed electrical nerve stimulator is used. The nerve stimulator delivers a very small electrical current, too small to be felt, to the nerve, which causes twitching of the particular muscles supplied by that nerve or plexus of nerves. In this example, the nerve serves as nothing more than a sophisticated “electrical wire”, which is now conducting the current delivered by an electrical device to the muscles, in place of the normally conducted current originating from the brain. The patient will therefore experience small muscle twitches in the muscles supplied by that nerve similar to when your eye is twitching. This technique has never been previously applied to an implanted device. In the proposed invention, the physician will be able to perform the nerve block test in their office, without sophisticated surgical techniques and sterile environment. The external programmer device will initiate a command sequence that will be received by the electronics of the implanted pump using RF waves.
  • [0053]
    In an alternate embodiment, the catheter can have two or more sets of electrodes, at least one set proximal to and at least one set distal to the area of renal nerve blockade. Each set of electrodes is in sufficient proximity to the renal nerve so that it can either sense intrinsic nerve activity or stimulate nerve activity. It is clear that if the pump control circuitry initiates and electrical pulse to a one set of electrodes on one side of the block and does not record a corresponding and appropriately timed signal on the opposite side of the block, then the drug is effective in creating the nerve block. Conversely, if the electrical activity is sensed, more drug must be infused to create the desired block. It is also clear that this information can be used as feedback by the control circuitry to automatically adjust the timing and/or amount of drug released.
  • [0054]
    FIG. 5 illustrates the anatomic placement of the drug infusion catheter 106 in the periarterial space of the renal artery. Catheter 106 is shown schematically in connection to the implanted pump 105. The kidney 102 is supplied with blood by the renal artery 107 from the aorta 301. The periarterial space is defined as space immediately surrounding the renal arteries and veins along its length between the connection to the aorta and the hilum 305 of the kidney. The renal artery can branch into two or more arteries. The renal vein and its branches connecting the kidney to the vena cava of the patient share the space. These additional elements of the renal vascular system are omitted on FIG. 5 and the following figures for clarity but are presumed there.
  • [0055]
    Renal nerve 501 is shown schematically as a branching network attached to the external surface of the renal artery 107. Anatomically, the renal nerve forms one or more plexi on the external surface of the renal artery. Fibers contributing to these plexi arise from the celiac ganglion, the lowest splanchnic nerve, the aorticorenal ganglion and aortic plexus. The plexi are distributed with branches of the renal artery to vessels of the kidney, the glomeruli and tubules. The nerves from these sources, fifteen or twenty in number, have a few ganglia developed upon them. They accompany the branches of the renal artery into the kidney; some filaments are distributed to the spermatic plexus and, on the right side, to the inferior vena cava.
  • [0056]
    A fibrous connective tissue layer, called the renal capsule, encloses each kidney. Around the renal capsule is a dense deposit of adipose tissue, the renal fat pad, which protects the kidney from mechanical shock. The kidneys and the surrounding adipose tissue are anchored to the abdominal wall by a thin layer of connective tissue, the renal fascia. The periarterial space of the renal artery is externally limited by renal fascia 502 that extends between the kidney and the aorta and contains renal vessels and nerves. Renal fascia presents a natural barrier to the dissipation of the infused drug 504 that is emitted from the tip of the catheter 106. Fat fills the space between the fascia and the renal artery. In particular, there is a fat tissue layer 503 in the hilum of the kidney that surrounds the renal pedicle where arteries, nerves and veins enter the kidney. The catheter tip 304 is shown penetrating the renal fascia and the renal fat and the anesthetic drug is infused into the fatpad tissue. Although shown in the hilum of the kidney, the tip can be placed anywhere in the renal periarterial space as long as the position allows the spread of the nerve blocking agent to at least a sufficient area of nerve to achieve the required level of nerve blockade. In practice, there is an advantage to placing the tip at a location in continuity with the periarterial space fat. Anesthetic drugs such as amino ester and amino amide local anesthetics such as bupivacaine have high lipid solubility. The invention takes advantage of this. A single bolus of bupivacaine, after being infused into these areas, will be adsorbed by fat and retained at the location of the renal nerve. In this manner, the renal fat serves as storage of drug that will then be slowly released from the renal fat, and in this way, obtains the desired prolonged nerve blocking action.
  • [0057]
    FIG. 6 illustrates an alternative embodiment of the invention where the catheter 106 has a sealed tip 601 but is equipped with multiple side holes or pores 602 in the wall of the catheter. The pores can be as small as a micron in diameter. Pores less than 20 microns in diameter will allow penetration of the nerve-blocking drug through the wall of the catheter and into the periarterial space, renal fat pad and ultimately to the renal nerve target. At the same time, these small pores will discourage ingrowth of tissue into the side holes and increase the probability of the catheter patency after being implanted in the body for a long time. This design helps redistribute the anesthetic in the periarterial space between the wall of the renal artery and the renal fascia 502. The catheter is equipped with a cuff 603 to encourage ingrowth of connective tissue and prevents escape of the infused drug through the puncture in the renal fascia. The cuff can be made of a natural or synthetic fiber material with pores larger than 20 microns and preferably 100 microns. For example, Dacron cuffs are commonly used in surgically implanted catheters for long term vascular access and dialysis in humans, Dacron cuffs support ingrowth of tissue, prevent dislodgment and provide a barrier to infection.
  • [0058]
    FIG. 7 illustrates an embodiment of the catheter 106 that bifurcates in the periarterial space of the kidney after it enters inside the renal fascia. The internal lumen of the catheter is split between two or more branches 701 and 702. Catheter brunches can have end holes; side holes or wall pores for the delivery of medication to the renal nerve.
  • [0059]
    FIG. 8 illustrates an embodiment of the catheter 106 that forms a coil 801 inside the periarterial space. The coil can be equipped with side holes or pores to evenly distribute the infused drug in the periarterial space around the renal artery.
  • [0060]
    FIG. 9 illustrates an alternative preferred embodiment of the invention. The nerve blocking agent is stored in the drug eluding implant 901. The implant 901 is contained in the periarterial space after the implantation surgery. Implant can be permanent or slowly biodegradable. Prior to implantation the implant is impregnated or “loaded” with a nerve-blocking agent that is gradually released over time into the periarterial space in the amount sufficient to block the renal nerve. An implantable drug eluding implant or pellet(s) made of a nonbiodegradable polymer has the drawback of requiring both surgical implantation and removal. Use of a biocompatible, biodegradable implant overcomes deficiencies of nonbiodegradable implants. A biodegradable implant can release a drug over a long period of time with simultaneous or subsequent degradation of the polymer within the tissue into constituents, thereby avoiding any need to remove the implant. A degradable polymer can be a surface eroding polymer. A surface eroding polymer degrades only from its exterior surface, and drug release is therefore proportional to the polymer erosion rate. A suitable such polymer can be a polyanhydride. It is advantageous to have a surface eroding implant where the eroding surface faces the renal artery and the renal nerve. Other surfaces of the implant may be designed to erode at a slower rate or not erode at all that directing the drug towards the renal nerve target.
  • [0061]
    Implants for long-term drug delivery are known. For example, such implants have been used or proposed for delivering a birth control drug systemically (into circulation) or a chemotherapeutic agent to a localized breast tumor. Examples of such implantable drug delivery devices include implantable diffusion systems (see, e.g., implants such as Norplant for birth control and Zoladex for the treatment of prostate cancer) and other such systems, described of example in U.S. Pat. Nos. 5,756,115; 5,429,634; 5,843,069. Norplant is an example of a class of the drug eluding implants also called controlled release systems comprising a polymer for prolonged delivery of a therapeutic drug. Norplant is a subdermal reservoir implant comprised of a polymer can be used to release a contraceptive steroid, such as progestin, in amounts of 25-30 mg/day for up to sixty months. Norplant uses the DURIN biodegradable implant technology that is a platform for controlled delivery of drugs for periods of weeks to six months or more. DURIN can be adopted for delivery of an anesthetic into the periarterial space. The technology is based on the use of biodegradable polyester excipients, which have a proven record of safety and effectiveness in approved drug delivery and medical device products. DURIN technology is available from the DURECT Corporation of Cupertino, Calif.
  • [0062]
    Drug eluding implants generally operate by simple diffusion, e.g., the active agent diffuses through a polymeric material at a rate that is controlled by the characteristics of the active agent formulation and the polymeric material. An alternative approach involves the use of biodegradable implants, which facilitate drug delivery through degradation or erosion of the implant material that contains the drug (see, e.g., U.S. Pat. No. 5,626,862). Alternatively, the implant may be based upon an osmotically-driven device to accomplish controlled drug delivery (see, e.g., U.S. Pat. Nos. 3,987,790, 4,865,845, 5,057,318, 5,059,423, 5,112,614, 5,137,727, 5,234,692; 5,234,693; and 5,728,396). These osmotic pumps generally operate by imbibing fluid from the outside environment and releasing corresponding amounts of the therapeutic agent. Osmotic pumps suitable for the renal nerve blocking application are available from ALZA Corporation of Mountain View, Calif. under the brand name of Alzet Osmotic Pumps and the Duros implant. Duros implant is a miniature cylinder made from a titanium alloy, which protects and stabilizes the drug inside. Water enters into one end of the cylinder through a semipermeable membrane; the drug is delivered from a port at the other end of the cylinder at a controlled rate appropriate to the specific therapeutic agent. The advantage of drug eluding implants is that they can store a common anesthetic agent in concentration much higher than that used for common local anesthetic injections. Accurate delivery of small amounts of the drug via diffusion enables storage of the many months supply of the nerve-blocking agent in the implant and eliminates the need for frequent refills typical of an implanted drug pump. It is also clear that more than one drug can be released from the implant, that function in either in a complementary or inhibiting manner, to enhance or block the activity of each other.
  • [0063]
    FIG. 9A illustrates an alternative embodiment of the local drug eluding system illustrated by FIG. 9. In this embodiment the sustained release of the nerve-blocking agent is accomplished by infusing or implanting a self-forming biodegradable compound impregnated with the nerve-blocking agent in the periarterial space around the renal artery. The nerve-blocking agent is delivered in a biodegradable matrix such as an injectable get or microspheres. The action of the nerve-blocking drug is thus prolonged and can be enhanced by adding other medicaments, such as steroids, that suppress inflammation at the application site. This embodiment has an advantage of allowing better distribution and conformance of the drug eluding implant to the anatomic space surrounding the renal nerve. The carrier matrix loaded with the nerve blocking drug can be applied as a patch by the surgeon to the surface of the renal artery. Then the periarterial space will be closed and the fascia repaired. Alternatively the carrier matrix can be delivered through a needle attached to an infusion device. Such needle can be inserted into the periarterial space under CT guidance as illustrated by FIG. 3. For delivery through a needle the matrix will need to be in the form of gel or injectable microspheres.
  • [0064]
    Patches and gels containing local anesthetics have been previously used for topical application to numb skin at the site of irritation or burn as well as for example during cataract eye surgery. One applicable gel is described in the U.S. Pat. No. 5,589,192 to Okabe, et al. “Gel pharmaceutical formulation for local anesthesia.”
  • [0065]
    Injectable microparticles or microspheres or microcapsules loaded with drugs are also known. Injectable microspheres are made of degradable materials, such as lactic acid-glycolic acid copolymers, polycaprolactones and cholesterol among others. For example, U.S. Pat. No. 5,061,492 related to prolonged release microcapsules of a water-soluble drug in a biodegradable polymer matrix which is composed of a copolymer of glycolic acid and a lactic acid. The injectable preparation is made by preparing a water-in-oil emulsion of aqueous layer of drug and drug retaining substance and an oil layer of the polymer, thickening and then water-drying. In addition, controlled release microparticles containing glucocorticoid (steroid) agents are described, for example, by Tice et al. in U.S. Pat. No. 4,530,840. In another embodiment, the implanted microspheres are stable and do not degrade on their own. In this case, the microspheres are broken via external, directed application of an energy source, such as ultrasound, temperature or radiation. Breaking of the microspheres release the encapsulated drug and provide the desired physiologic effect, in this case, nerve blockade.
  • [0066]
    U.S. Pat. No. 5,700,485 to Berde, et al. titled “Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid” describes in sufficient detail methods of manufacturing and application of biodegradable controlled release microspheres for the prolonged administration of a local anesthetic agent. The microspheres are formed of biodegradable polymers polyanhydrides, polylactic acid-glycolic acid copolymers. Local anesthetics are incorporated into the polymer. Prolonged release is obtained by incorporation of a glucocorticoid into the polymeric matrix or by co-administration of the glucocorticoid with the microspheres. Significantly U.S. Pat. No. 6,238,702 to the same authors entitled “High load formulations and methods for providing prolonged local anesthesia” described the polymer matrix that contained significantly higher concentration of local anesthetic than is normally used for injections. Since the periarterial space can anatomically accommodate an implant of substantial size nerve blocking for at least 30 days and more preferably several years is possible. U.S. Pat. No. 5,618,563 to Berde, et al. titled “Biodegradable polymer matrices for sustained delivery of local anesthetic agents” further elaborates on the biodegradable controlled release system consisting of a polymeric matrix incorporating a local anesthetic for the prolonged administration of the local anesthetic agent, and a method for the manufacture thereof.
  • [0067]
    FIG. 10 illustrates the design of the drug delivery catheter for the invention that improves fixation of the catheter and distribution of the infused drug in the periarterial space. After the implantation an implant and the surrounding tissue undergo changes. It is the purpose of this part of the invention to improve the interface of the drag delivery device to maximize the effect of the drug on the nerve while minimizing the amount.
  • [0068]
    The human body acts spontaneously to reject or encapsulate any foreign object, which has been introduced into the body or a specific bodily organ. In some cases, encapsulation will impede or halt drug infusion. In others, the delivery fluid will reflux from the tissue through a space opened between the exterior of the catheter and the tissue of the bore in which the catheter is received. Either of these results will greatly diminish the effect of direct infusion of medicaments on affected body tissue. Thus, the body's own natural defense systems thus tend to frustrate the procedure. The reaction of living tissue to an implant can take a number of different forms. For example, the initial response to the surgical trauma of implantation is usually called the acute inflammatory reaction and is characterized by an invasion of polymorphonuclear leukocytes (PMNs). The acute inflammatory reaction is followed by the chronic inflammatory reaction, which is characterized by the presence of numerous macrophages and lymphocytes, some monocytes and granulocytes. Fibroblasts also begin accumulating in the vicinity of the implant and begin producing a matrix of collagen. The fibroblasts and collagen form a connective tissue capsule around the implant and the chronic inflammatory cells to effectively isolate the implant and these cells from the rest of the body. Connective tissue consisting of a fine network of collagen with active producing fibroblasts accompanied by chronic inflammatory cells, capillaries and blood vessels is referred to collectively as granulation tissue.
  • [0069]
    Thus, when a material is implanted into a soft tissue bed of a living organism such as a human or an animal, a granulation tissue capsule is formed around the implant material consisting of inflammatory cells, immature fibroblasts and blood vessels. This tissue capsule usually increases in thickness with time and contracts around the implant, deforming the implantation site, and possibly the implant itself depending upon the rigidity of the implant.
  • [0070]
    Implant illustrated by FIG. 10 is the tip 304 of the drug delivery catheter 106 connected to the implanted drug pump explained earlier in this application. The tip 304 is in the fluid communication with the internal lumen 1001 of the catheter and is shown with an internal cavity 1002 to which the nerve-blocking drug is delivered by the pump 104 (See FIG. 4). The tip is made out of the porous material, preferably a porous plastic such as for example PTFE. It is known that, when the implant is porous with pore entry diameters larger than approximately 20 microns, tissue grows into these pores. This phenomenon appears desirable to many medical device application because it makes an implant one with the implanted organ and in theory it allows tissue ingrowth into the implant and reduces capsular contraction. For example, U.S. Pat. No. 4,011,861 to Enger discloses an implantable electric terminal which has pores preferably in the range of about 10 to 500 microns so that blood vessels and tissue can grow into the pores.
  • [0071]
    The embodiment illustrated by FIG. 10 combines a material with small pores, preferably less than 20 microns 304 designed to discourage the tissue ingrowth and a material with larger pores, preferably larger than 20 microns 1004 to encourage tissue ingrowth. Material 1003 allows free diffusion and convection of the drug from the cavity 1002 to the periarterial space. Material 1004 encourages the natural fixation of the catheter tip 304 so that it will not be dislodged by motion and migrate out of the periarterial space.
  • [0072]
    FIG. 11 illustrates the catheter tip made of porous materials. It shows the surrounding tissue 1101 ingrowth 1102 into the large pore implant 1004 section. The small pore section 1003 is oriented to direct the drug infusion towards the renal artery 107 and the renal nerve 501.
  • [0073]
    FIG. 12 further illustrates an embodiment of the porous tip of the catheter 106 for directional drug delivery. The portion of the implant that surrounds the drug filled cavity 1002 and that is oriented away from the renal nerve is made of the material 1004 that is impermeable to drug. Portion of the implant that is oriented towards the renal nerve (on the surface of the renal artery) 1003 is made of the material that is permeable to the nerve blocking agent. Drug flux 1201 is shown as unidirectional therefore directing the therapy towards the site and minimizing the loss of the drug.
  • [0074]
    FIGS. 13 and 14 further illustrate an embodiment of the porous tip of the catheter 106 that at least partially encloses or envelopes the renal artery 107 with the intention of further directing the drug delivery towards the renal nerve. The tip forms a multi-layer cuff around the artery. The outer shell 1004 of the cuff is made of the material that is impermeable to the infused drug to prevent dissipation of the said drug away from the renal nerve. The material 1004 can also have large pores to encourage ingrowth and fixation of the implant. The inner layer 1003 is made of material permeable to the nerve-blocking drug. It is in fluid communication with the delivery catheter 106. The layer 1003 can be equipped with internal channels to facilitate equal distribution of drug 1201 in the space 1301 between the cuff and the artery 107.
  • [0075]
    While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiment, it is to be understood that the invention is not to be limited to the disclosed embodiment, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.
Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US2276995 *30 août 194017 mars 1942A J GinsbergElectrotherapy
US2276996 *30 nov. 194017 mars 1942A J GinsbergNon-radio-interfering therapeutic apparatus
US3563246 *24 avr. 196716 févr. 1971Intelectron CorpMethod and apparatus for improving neural performance in human subjects by electrotherapy
US3650277 *17 févr. 197021 mars 1972Lkb Medical AbApparatus for influencing the systemic blood pressure in a patient by carotid sinus nerve stimulation
US3794022 *30 juin 197226 févr. 1974E NawracajDual oscillator, variable pulse duration electrotherapeutic device
US4011861 *28 oct. 197515 mars 1977Case Western Reserve UniversityImplantable electric terminal for organic tissue
US4071033 *20 déc. 197631 janv. 1978Nawracaj Edward PElectrotherapeutic device with modulated dual signals
US4141365 *24 févr. 197727 févr. 1979The Johns Hopkins UniversityEpidural lead electrode and insertion needle
US4315503 *5 déc. 197916 févr. 1982Electro-Biology, Inc.Modification of the growth, repair and maintenance behavior of living tissues and cells by a specific and selective change in electrical environment
US4649936 *11 oct. 198417 mars 1987Case Western Reserve UniversityAsymmetric single electrode cuff for generation of unidirectionally propagating action potentials for collision blocking
US4816016 *18 mars 198828 mars 1989Pudenz-Schulte Medical Research Corp.Subcutaneous infusion reservoir and pump system
US4981146 *6 févr. 19901 janv. 1991Maven Labs, Inc.Nausea control device
US4998532 *21 févr. 198912 mars 1991Lti Biomedical, Inc.Portable electro-therapy system
US5094242 *9 déc. 198810 mars 1992Regents Of The University Of CaliforniaImplantable nerve stimulation device
US5188837 *3 oct. 199123 févr. 1993Nova Pharmaceutical CorporationLipsopheres for controlled delivery of substances
US5193048 *27 avr. 19909 mars 1993Kaufman Dennis RStun gun with low battery indicator and shutoff timer
US5193539 *18 déc. 199116 mars 1993Alfred E. Mann Foundation For Scientific ResearchImplantable microstimulator
US5193540 *18 déc. 199116 mars 1993Alfred E. Mann Foundation For Scientific ResearchStructure and method of manufacture of an implantable microstimulator
US5282468 *8 janv. 19921 févr. 1994Medtronic, Inc.Implantable neural electrode
US5282785 *5 oct. 19921 févr. 1994Cortrak Medical, Inc.Drug delivery apparatus and method
US5286254 *28 août 199215 févr. 1994Cortrak Medical, Inc.Drug delivery apparatus and method
US5389069 *17 sept. 199314 févr. 1995Massachusetts Institute Of TechnologyMethod and apparatus for in vivo electroporation of remote cells and tissue
US5397308 *22 oct. 199314 mars 1995Scimed Life Systems, Inc.Balloon inflation measurement apparatus
US5397338 *30 déc. 199314 mars 1995Maven Labs, Inc.Electrotherapy device
US5400784 *15 oct. 199328 mars 1995Case Western Reserve UniversitySlowly penetrating inter-fascicular nerve cuff electrode and method of using
US5484400 *23 mars 199416 janv. 1996Vidamed, Inc.Dual channel RF delivery system
US5494822 *29 juil. 199427 févr. 1996Bio-Preserve Medical CorporationOrgan perfusion device
US5498238 *27 août 199312 mars 1996Cortrak Medical, Inc.Simultaneous angioplasty and phoretic drug delivery
US5499971 *14 déc. 199319 mars 1996Cortrak Medical, Inc.Method for iontophoretically delivering drug adjacent to a heart
US5704908 *10 oct. 19966 janv. 1998Genetronics, Inc.Electroporation and iontophoresis catheter with porous balloon
US5707400 *19 sept. 199513 janv. 1998Cyberonics, Inc.Treating refractory hypertension by nerve stimulation
US5711326 *8 août 199627 janv. 1998Whirlpool CorporationDishwasher accumulator soil removal grating for a filter system
US5713847 *6 févr. 19963 févr. 1998The University Of Iowa Research FoundationHuman drug delivery device for tinnitus
US5722401 *13 nov. 19953 mars 1998Cardiac Pathways CorporationEndocardial mapping and/or ablation catheter probe
US5723001 *6 mai 19963 mars 1998Electropharmacology, Inc.Apparatus and method for therapeutically treating human body tissue with electromagnetic radiation
US5725563 *20 avr. 199410 mars 1998Klotz; AntoineElectronic device and method for adrenergically stimulating the sympathetic system with respect to the venous media
US5728396 *30 janv. 199717 mars 1998Alza CorporationSustained delivery of leuprolide using an implantable system
US5861021 *20 déc. 199619 janv. 1999Urologix IncMicrowave thermal therapy of cardiac tissue
US5865787 *13 sept. 19962 févr. 1999Cortrak Medical, Inc.Simultaneous cardiac pacing and local drug delivery
US5871449 *27 déc. 199616 févr. 1999Brown; David LloydDevice and method for locating inflamed plaque in an artery
US6009877 *19 févr. 19984 janv. 2000Edwards; Stuart D.Method for treating a sphincter
US6010613 *8 déc. 19954 janv. 2000Cyto Pulse Sciences, Inc.Method of treating materials with pulsed electrical fields
US6026326 *13 janv. 199715 févr. 2000Medtronic, Inc.Apparatus and method for treating chronic constipation
US6041252 *7 juin 199521 mars 2000Ichor Medical Systems Inc.Drug delivery system and method
US6171306 *9 déc. 19969 janv. 2001Ep Technologies, Inc.Systems and methods for forming large lesions in body tissue using curvilinear electrode elements
US6178349 *15 avr. 199923 janv. 2001Medtronic, Inc.Drug delivery neural stimulation device for treatment of cardiovascular disorders
US6190353 *11 oct. 199620 févr. 2001Transvascular, Inc.Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures
US6192889 *5 mai 199827 févr. 2001Woodside Biomedical, Inc.Method of suppression and prevention of the gag reflex
US6205361 *28 janv. 199920 mars 2001Advanced Bionics CorporationImplantable expandable multicontact electrodes
US6208894 *25 mars 199827 mars 2001Alfred E. Mann Foundation For Scientific Research And Advanced BionicsSystem of implantable devices for monitoring and/or affecting body parameters
US6347247 *7 mai 199912 févr. 2002Genetronics Inc.Electrically induced vessel vasodilation
US6506189 *21 août 200014 janv. 2003Sherwood Services AgCool-tip electrode thermosurgery system
US6508774 *9 mars 200021 janv. 2003Transurgical, Inc.Hifu applications with feedback control
US6514226 *10 févr. 20004 févr. 2003Chf Solutions, Inc.Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney
US6516211 *6 juil. 20004 févr. 2003Transurgical, Inc.MRI-guided therapeutic unit and methods
US6517811 *5 janv. 200111 févr. 2003Research Corporation Technologies, Inc.Compounds for cancer imaging and therapy
US6522926 *27 sept. 200018 févr. 2003Cvrx, Inc.Devices and methods for cardiovascular reflex control
US6522932 *13 févr. 200118 févr. 2003Advanced Bionics CorporationImplantable, expandable, multicontact electrodes and tools for use therewith
US6524607 *10 mars 200025 févr. 2003Euro-Celtique, S.A.Formulations and methods for providing prolonged local anesthesia
US6672312 *31 janv. 20026 janv. 2004Transurgical, Inc.Pulmonary vein ablation with myocardial tissue locating
US6676657 *6 déc. 200113 janv. 2004The United States Of America As Represented By The Department Of Health And Human ServicesEndoluminal radiofrequency cauterization system
US6681136 *4 déc. 200120 janv. 2004Science Medicus, Inc.Device and method to modulate blood pressure by electrical waveforms
US6684105 *31 août 200127 janv. 2004Biocontrol Medical, Ltd.Treatment of disorders by unidirectional nerve stimulation
US6690971 *30 nov. 200010 févr. 2004Biotronik Mess - Und Therapiegeraete Gmbh & Co. Ingenieurbuero BerlinDevice for regulating heart rate and heart pumping force
US6692738 *26 janv. 200117 févr. 2004The General Hospital CorporationDelivery of therapeutic biologicals from implantable tissue matrices
US6697670 *11 févr. 200324 févr. 2004Minnesota Medical Physics, LlcApparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
US6845267 *30 août 200118 janv. 2005Advanced Bionics CorporationSystems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation
US6850801 *26 sept. 20011 févr. 2005Cvrx, Inc.Mapping methods for cardiovascular reflex control devices
US6985774 *26 sept. 200110 janv. 2006Cvrx, Inc.Stimulus regimens for cardiovascular reflex control
US6994700 *18 mars 20057 févr. 2006Flowmedica, Inc.Apparatus and method for inserting an intra-aorta catheter through a delivery sheath
US6994706 *13 août 20027 févr. 2006Minnesota Medical Physics, LlcApparatus and method for treatment of benign prostatic hyperplasia
US7004911 *24 févr. 200328 févr. 2006Hosheng TuOptical thermal mapping for detecting vulnerable plaque
US7162303 *8 avr. 20039 janv. 2007Ardian, Inc.Renal nerve stimulation method and apparatus for treatment of patients
US7647115 *3 juin 200512 janv. 2010Ardian, Inc.Renal nerve stimulation method and apparatus for treatment of patients
US7653438 *13 mai 200526 janv. 2010Ardian, Inc.Methods and apparatus for renal neuromodulation
US20020002329 *24 août 20013 janv. 2002Boaz AvitallMapping and ablation catheter system
US20020026222 *30 nov. 200028 févr. 2002Biotronik Mess- Und Therapiegeraete Gmbh & CoDevice for regulating heart rate and heart pumping force
US20020026228 *30 nov. 200028 févr. 2002Patrick SchauerteElectrode for intravascular stimulation, cardioversion and/or defibrillation
US20030004549 *26 oct. 20012 janv. 2003Medtronic, Inc.Method and apparatus to minimize the effects of a cardiac insult
US20030009145 *22 mars 20029 janv. 2003Struijker-Boudier Harry A.J.Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US20030018367 *19 juil. 200223 janv. 2003Dilorenzo Daniel JohnMethod and apparatus for neuromodulation and phsyiologic modulation for the treatment of metabolic and neuropsychiatric disease
US20030040774 *21 août 200127 févr. 2003Terry Reese S.Treatment of congestive heart failure and autonomic cardiovascular drive disorders
US20040010303 *27 mars 200315 janv. 2004Cvrx, Inc.Electrode structures and methods for their use in cardiovascular reflex control
US20040019364 *27 mars 200329 janv. 2004Cvrx, Inc.Devices and methods for cardiovascular reflex control via coupled electrodes
US20040019371 *17 août 200129 janv. 2004Ali JaafarApparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US20050010263 *29 juil. 200213 janv. 2005Patrick SchauerteNeurostimulation unit for immobilizing the heart during cardiosurgical operations
US20050021092 *18 juin 200427 janv. 2005Yun Anthony JoonkyooTreatment of conditions through modulation of the autonomic nervous system
US20050038409 *27 sept. 200417 févr. 2005Jerome SegalMechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US20060004417 *27 juin 20055 janv. 2006Cvrx, Inc.Baroreflex activation for arrhythmia treatment
US20060004430 *27 juin 20055 janv. 2006Cvrx, Inc.Connection structures for extra-vascular electrode lead body
US20060025821 *20 mai 20052 févr. 2006Mark GelfandMethods and devices for renal nerve blocking
US20060030814 *18 mars 20059 févr. 2006Flowmedica, Inc.Method and apparatus for selective drug infusion via an intra-aortic flow diverter delivery catheter
US20060036218 *16 mars 200516 févr. 2006Flowmedica, Inc.Method and apparatus for selective material delivery via an intra-renal catheter
US20060041277 *25 juil. 200523 févr. 2006Mark DeemMethods and apparatus for renal neuromodulation
US20060041283 *19 août 200423 févr. 2006Mark GelfandImplantable device and method for treatment of hypertension
US20080004673 *2 avr. 20073 janv. 2008Cvrx, Inc.Implantable extravascular electrostimulation system having a resilient cuff
US20080015659 *25 sept. 200717 janv. 2008Yi ZhangNeurostimulation systems and methods for cardiac conditions
US20080039904 *7 août 200714 févr. 2008Cherik BulkesIntravascular implant system
US20090024195 *11 avr. 200822 janv. 2009The Cleveland Clinic FoundationMethod and apparatus for renal neuromodulation
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US792535227 mars 200912 avr. 2011Synecor LlcSystem and method for transvascularly stimulating contents of the carotid sheath
US80881278 mai 20093 janv. 2012Innovative Pulmonary Solutions, Inc.Systems, assemblies, and methods for treating a bronchial tree
US81168832 févr. 200714 févr. 2012Synecor LlcIntravascular device for neuromodulation
US813137113 avr. 20066 mars 2012Ardian, Inc.Methods and apparatus for monopolar renal neuromodulation
US813137219 mars 20076 mars 2012Ardian, Inc.Renal nerve stimulation method for treatment of patients
US814531625 juil. 200527 mars 2012Ardian, Inc.Methods and apparatus for renal neuromodulation
US81453176 mars 200627 mars 2012Ardian, Inc.Methods for renal neuromodulation
US81505183 juin 20053 avr. 2012Ardian, Inc.Renal nerve stimulation method and apparatus for treatment of patients
US81505196 mars 20063 avr. 2012Ardian, Inc.Methods and apparatus for bilateral renal neuromodulation
US81505206 mars 20063 avr. 2012Ardian, Inc.Methods for catheter-based renal denervation
US81728271 juin 20068 mai 2012Innovative Pulmonary Solutions, Inc.Apparatus for treating asthma using neurotoxin
US81757116 mars 20068 mai 2012Ardian, Inc.Methods for treating a condition or disease associated with cardio-renal function
US822663826 sept. 201124 juil. 2012Innovative Pulmonary Solutions, Inc.Systems, assemblies, and methods for treating a bronchial tree
US834789114 nov. 20068 janv. 2013Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US83699547 mars 20115 févr. 2013Synecor LlcSystem and method for transvascularly stimulating contents of the carotid sheath
US838605331 oct. 200826 févr. 2013Medtronic, Inc.Subclavian ansae stimulation
US843342313 déc. 201030 avr. 2013Ardian, Inc.Methods for multi-vessel renal neuromodulation
US844464014 sept. 201221 mai 2013Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US845459411 août 20094 juin 2013Medtronic Ardian Luxembourg S.A.R.L.Apparatus for performing a non-continuous circumferential treatment of a body lumen
US848383117 févr. 20099 juil. 2013Holaira, Inc.System and method for bronchial dilation
US848919214 juin 201216 juil. 2013Holaira, Inc.System and method for bronchial dilation
US850414725 sept. 20096 août 2013Medtronic Ardian Luxembourg S.A.R.L.Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US854860014 sept. 20121 oct. 2013Medtronic Ardian Luxembourg S.A.R.L.Apparatuses for renal neuromodulation and associated systems and methods
US85683997 mars 201329 oct. 2013Metavention, Inc.Methods for thermally-induced hepatic neuromodulation
US85798917 mars 201312 nov. 2013Metavention, Inc.Devices for thermally-induced hepatic neuromodulation
US862042314 mars 201131 déc. 2013Medtronic Ardian Luxembourg S.A.R.L.Methods for thermal modulation of nerves contributing to renal function
US862630011 mars 20117 janv. 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for thermally-induced renal neuromodulation
US865212921 août 200918 févr. 2014Medtronic Ardian Luxembourg S.A.R.L.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US867630928 juin 201318 mars 2014Medtronic Ardian Luxembourg S.A.R.L.Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US86849989 mars 20121 avr. 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for inhibiting renal nerve activity
US872163712 juil. 201313 mai 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for performing renal neuromodulation via catheter apparatuses having inflatable balloons
US87252498 mars 201213 mai 2014Nephera Ltd.Stimulation of the urinary system
US872806923 oct. 201320 mai 2014Metavention, Inc.Modulation of nerves that innervate the liver
US872807023 oct. 201320 mai 2014Metavention, Inc.Hepatic neuromodulation methods
US872807530 août 201020 mai 2014Medtronic Ardian Luxembourg S.A.R.L.Multi-directional deflectable catheter apparatuses, systems, and methods for renal neuromodulation
US872813712 févr. 201320 mai 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for thermally-induced renal neuromodulation
US872813812 févr. 201320 mai 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for thermally-induced renal neuromodulation
US873167218 juin 201320 mai 2014Holaira, Inc.System and method for bronchial dilation
US874089528 juin 20133 juin 2014Holaira, Inc.Delivery devices with coolable energy emitting assemblies
US874089612 juil. 20133 juin 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for performing renal neuromodulation via catheter apparatuses having inflatable balloons
US87583341 nov. 201324 juin 2014Metavention, Inc.Hepatic neuromodulation devices
US876847011 mai 20101 juil. 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for monitoring renal neuromodulation
US877125220 mai 20058 juil. 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and devices for renal nerve blocking
US877491314 nov. 20068 juil. 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for intravasculary-induced neuromodulation
US877492221 mai 20138 juil. 2014Medtronic Ardian Luxembourg S.A.R.L.Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US877794222 oct. 201015 juil. 2014Medtronic Ardian Luxembourg S.A.R.L.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US877794328 juin 201315 juil. 2014Holaira, Inc.Delivery devices with coolable energy emitting assemblies
US878446312 févr. 201322 juil. 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for thermally-induced renal neuromodulation
US880554516 avr. 201312 août 2014Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for multi-vessel renal neuromodulation
US880828020 avr. 201219 août 2014Holaira, Inc.Systems, assemblies, and methods for treating a bronchial tree
US880834513 avr. 201019 août 2014Medtronic Ardian Luxembourg S.A.R.L.Handle assemblies for intravascular treatment devices and associated systems and methods
US88185142 juil. 201326 août 2014Medtronic Ardian Luxembourg S.A.R.L.Methods for intravascularly-induced neuromodulation
US882148920 avr. 20122 sept. 2014Holaira, Inc.Systems, assemblies, and methods for treating a bronchial tree
US88456295 avr. 201030 sept. 2014Medtronic Ardian Luxembourg S.A.R.L.Ultrasound apparatuses for thermally-induced renal neuromodulation
US885216328 juin 20137 oct. 2014Medtronic Ardian Luxembourg S.A.R.L.Renal neuromodulation via drugs and neuromodulatory agents and associated systems and methods
US887086328 mai 201028 oct. 2014Medtronic Ardian Luxembourg S.A.R.L.Catheter apparatuses, systems, and methods for renal neuromodulation
US887681511 juin 20144 nov. 2014Metavention, Inc.Energy delivery devices for hepatic neuromodulation
US888018525 juin 20134 nov. 2014Boston Scientific Scimed, Inc.Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US888018611 avr. 20134 nov. 2014Medtronic Ardian Luxembourg S.A.R.L.Renal neuromodulation for treatment of patients with chronic heart failure
US889463916 mai 201425 nov. 2014Metavention, Inc.Hepatic artery nerve modulation methods
US89002238 nov. 20102 déc. 2014Tsunami Medtech, LlcTissue ablation systems and methods of use
US891143911 nov. 201016 déc. 2014Holaira, Inc.Non-invasive and minimally invasive denervation methods and systems for performing the same
US89239709 juin 201130 déc. 2014Nephera Ltd.Stimulation of the urinary system
US893228926 sept. 201113 janv. 2015Holaira, Inc.Delivery devices with coolable energy emitting assemblies
US893497822 avr. 201413 janv. 2015Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for renal neuromodulation
US893997029 févr. 201227 janv. 2015Vessix Vascular, Inc.Tuned RF energy and electrical tissue characterization for selective treatment of target tissues
US894886515 nov. 20133 févr. 2015Medtronic Ardian Luxembourg S.A.R.L.Methods for treating heart arrhythmia
US89512517 nov. 201210 févr. 2015Boston Scientific Scimed, Inc.Ostial renal nerve ablation
US895887114 janv. 201117 févr. 2015Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US896150720 avr. 201224 févr. 2015Holaira, Inc.Systems, assemblies, and methods for treating a bronchial tree
US896150820 avr. 201224 févr. 2015Holaira, Inc.Systems, assemblies, and methods for treating a bronchial tree
US89744457 janv. 201010 mars 2015Recor Medical, Inc.Methods and apparatus for treatment of cardiac valve insufficiency
US897445125 oct. 201110 mars 2015Boston Scientific Scimed, Inc.Renal nerve ablation using conductive fluid jet and RF energy
US897523326 janv. 201110 mars 2015Northwind Medical, Inc.Methods for renal denervation
US898359521 nov. 201317 mars 2015Medtronic Ardian Luxembourg S.A.R.L.Renal neuromodulation for treatment of patients with chronic heart failure
US89862944 févr. 201024 mars 2015Medtronic Ardian Luxembourg S.a.rl.Apparatuses for thermally-induced renal neuromodulation
US90051908 nov. 201314 avr. 2015Metavention, Inc.Treatment of non-alcoholic fatty liver disease
US90051918 nov. 201314 avr. 2015Metavention, Inc.Neuromodulation methods using balloon catheter
US900519526 sept. 201114 avr. 2015Holaira, Inc.Delivery devices with coolable energy emitting assemblies
US901142225 sept. 201421 avr. 2015Metavention, Inc.Hepatic neuromodulation to treat fatty liver conditions
US901732428 juin 201328 avr. 2015Holaira, Inc.Delivery devices with coolable energy emitting assemblies
US902303422 nov. 20115 mai 2015Boston Scientific Scimed, Inc.Renal ablation electrode with force-activatable conduction apparatus
US902303723 avr. 20135 mai 2015Medtronic Ardian Luxembourg S.A.R.L.Balloon catheter apparatus for renal neuromodulation
US902847015 juin 201212 mai 2015University Of Utah Research FoundationImage-guided renal nerve ablation
US902847221 déc. 201212 mai 2015Vessix Vascular, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US902848523 sept. 201112 mai 2015Boston Scientific Scimed, Inc.Self-expanding cooling electrode for renal nerve ablation
US90339698 nov. 201319 mai 2015Metavention, Inc.Nerve modulation to treat diabetes
US903725921 déc. 201219 mai 2015Vessix Vascular, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US905010621 déc. 20129 juin 2015Boston Scientific Scimed, Inc.Off-wall electrode device and methods for nerve modulation
US905618428 avr. 201116 juin 2015Northwind Medical, Inc.Methods for renal denervation
US90607619 nov. 201123 juin 2015Boston Scientific Scime, Inc.Catheter-focused magnetic field induced renal nerve ablation
US90607848 nov. 201323 juin 2015Metavention, Inc.Hepatic denervation systems
US907252715 juil. 20137 juil. 2015Medtronic Ardian Luxembourg S.A.R.L.Apparatuses and methods for renal neuromodulation
US907290221 déc. 20127 juil. 2015Vessix Vascular, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US907900016 oct. 201214 juil. 2015Boston Scientific Scimed, Inc.Integrated crossing balloon catheter
US908460918 juil. 201121 juil. 2015Boston Scientific Scime, Inc.Spiral balloon catheter for renal nerve ablation
US90893509 nov. 201128 juil. 2015Boston Scientific Scimed, Inc.Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US90895418 nov. 201328 juil. 2015Metavention, Inc.Gastroduodenal artery neuromodulation
US908954225 sept. 201428 juil. 2015Metavention, Inc.Hepatic neuromodulation using microwave energy
US910804026 juin 201418 août 2015Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for multi-vessel renal neuromodulation
US911394419 nov. 201225 août 2015Tsunami Medtech, LlcMethod for performing lung volume reduction
US911412331 oct. 201425 août 2015Metavention, Inc.Hepatic neuromodulation using fluids or chemical agents
US911412426 déc. 201425 août 2015Metavention, Inc.Modulation of nerves innervating the liver
US911960015 nov. 20121 sept. 2015Boston Scientific Scimed, Inc.Device and methods for renal nerve modulation monitoring
US911963216 nov. 20121 sept. 2015Boston Scientific Scimed, Inc.Deflectable renal nerve ablation catheter
US912564330 avr. 20148 sept. 2015Holaira, Inc.System and method for bronchial dilation
US912566117 oct. 20138 sept. 2015Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for renal neuromodulation
US912566628 sept. 20078 sept. 2015Vessix Vascular, Inc.Selectable eccentric remodeling and/or ablation of atherosclerotic material
US912566718 oct. 20078 sept. 2015Vessix Vascular, Inc.System for inducing desirable temperature effects on body tissue
US913197823 avr. 201415 sept. 2015Medtronic Ardian Luxembourg S.A.R.L.Methods for bilateral renal neuromodulation
US913198318 oct. 201315 sept. 2015Ablative Solutions, Inc.Methods ablating tissue using a catheter-based injection system
US913828123 sept. 201322 sept. 2015Medtronic Ardian Luxembourg S.A.R.L.Methods for bilateral renal neuromodulation via catheter apparatuses having expandable baskets
US914932811 nov. 20106 oct. 2015Holaira, Inc.Systems, apparatuses, and methods for treating tissue and controlling stenosis
US91493298 nov. 20136 oct. 2015Metavention, Inc.Glucose alteration methods
US915558922 juil. 201113 oct. 2015Boston Scientific Scimed, Inc.Sequential activation RF electrode set for renal nerve ablation
US916180130 déc. 201020 oct. 2015Tsunami Medtech, LlcMedical system and method of use
US916204628 sept. 201220 oct. 2015Boston Scientific Scimed, Inc.Deflectable medical devices
US917369617 sept. 20133 nov. 2015Boston Scientific Scimed, Inc.Self-positioning electrode system and method for renal nerve modulation
US917405021 déc. 20123 nov. 2015Vessix Vascular, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US91799624 déc. 201310 nov. 2015Ablative Solutions, Inc.Transvascular methods of treating extravascular tissue
US918619814 sept. 201217 nov. 2015Medtronic Ardian Luxembourg S.A.R.L.Ultrasound apparatuses for thermally-induced renal neuromodulation and associated systems and methods
US918620920 juil. 201217 nov. 2015Boston Scientific Scimed, Inc.Nerve modulation system having helical guide
US918621010 oct. 201217 nov. 2015Boston Scientific Scimed, Inc.Medical devices including ablation electrodes
US918621125 janv. 201317 nov. 2015Boston Scientific Scimed, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US918621315 mai 201417 nov. 2015Medtronic Ardian Luxembourg S.A.R.L.Methods for renal neuromodulation
US919243522 nov. 201124 nov. 2015Boston Scientific Scimed, Inc.Renal denervation catheter with cooled RF electrode
US919271521 mars 201424 nov. 2015Medtronic Ardian Luxembourg S.A.R.L.Methods for renal nerve blocking
US919279013 avr. 201124 nov. 2015Boston Scientific Scimed, Inc.Focused ultrasonic renal denervation
US920488912 sept. 20118 déc. 2015Tsunami Medtech, LlcMedical instrument and method of use
US922055826 oct. 201129 déc. 2015Boston Scientific Scimed, Inc.RF renal denervation catheter with multiple independent electrodes
US922056119 janv. 201229 déc. 2015Boston Scientific Scimed, Inc.Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
US92379252 août 201119 janv. 2016Ablative Solutions, Inc.Expandable catheter system for peri-ostial injection and muscle and nerve fiber ablation
US925436030 juin 20149 févr. 2016Ablative Solutions, Inc.Peri-vascular tissue ablation catheter with deflection surface support structures
US926555823 avr. 201423 févr. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for bilateral renal neuromodulation
US92655758 nov. 201323 févr. 2016Metavention, Inc.Balloon catheter neuromodulation systems
US926596910 déc. 201223 févr. 2016Cardiac Pacemakers, Inc.Methods for modulating cell function
US927795511 avr. 20118 mars 2016Vessix Vascular, Inc.Power generating and control apparatus for the treatment of tissue
US927819624 août 20118 mars 2016Ablative Solutions, Inc.Expandable catheter system for vessel wall injection and muscle and nerve fiber ablation
US92892553 mars 201522 mars 2016Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for renal neuromodulation
US92978454 mars 201429 mars 2016Boston Scientific Scimed, Inc.Medical devices and methods for treatment of hypertension that utilize impedance compensation
US930179520 nov. 20135 avr. 2016Ablative Solutions, Inc.Transvascular catheter for extravascular delivery
US930804320 nov. 201412 avr. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for monopolar renal neuromodulation
US930804420 nov. 201412 avr. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for therapeutic renal neuromodulation
US931463020 nov. 201419 avr. 2016Medtronic Ardian Luxembourg S.A.R.L.Renal neuromodulation for treatment of patients
US931464426 juin 200819 avr. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods and systems for thermally-induced renal neuromodulation
US932056120 nov. 201426 avr. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for bilateral renal neuromodulation
US932085030 juin 201426 avr. 2016Ablative Solutions, Inc.Peri-vascular tissue ablation catheter with unique injection fitting
US932675114 nov. 20113 mai 2016Boston Scientific Scimed, Inc.Catheter guidance of external energy for renal denervation
US93268171 déc. 20143 mai 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for treating heart arrhythmia
US932710012 mars 20133 mai 2016Vessix Vascular, Inc.Selective drug delivery in a lumen
US93271222 févr. 20153 mai 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for catheter-based renal neuromodulation
US93396185 nov. 201217 mai 2016Holaira, Inc.Method and apparatus for controlling narrowing of at least one airway
US934590026 juin 200824 mai 2016Medtronic Ardian Luxembourg S.A.R.L.Methods and systems for thermally-induced renal neuromodulation
US935836530 juil. 20117 juin 2016Boston Scientific Scimed, Inc.Precision electrode movement control for renal nerve ablation
US936428017 déc. 201414 juin 2016Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US936428410 oct. 201214 juin 2016Boston Scientific Scimed, Inc.Method of making an off-wall spacer cage
US938106313 juil. 20125 juil. 2016Magnetecs Inc.Method and apparatus for magnetically guided catheter for renal denervation employing MOSFET sensor array
US939893327 déc. 201326 juil. 2016Holaira, Inc.Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US94026846 févr. 20132 août 2016Boston Scientific Scimed, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US94029922 juil. 20152 août 2016Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for multi-vessel renal neuromodulation
US940866118 juil. 20119 août 2016Patrick A. HaverkostRF electrodes on multiple flexible wires for renal nerve ablation
US94209558 oct. 201223 août 2016Boston Scientific Scimed, Inc.Intravascular temperature monitoring system and method
US94334578 mars 20106 sept. 2016Tsunami Medtech, LlcMedical instruments and techniques for thermally-mediated therapies
US943376011 déc. 20126 sept. 2016Boston Scientific Scimed, Inc.Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US943972614 mars 201613 sept. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for therapeutic renal neuromodulation
US944586721 mars 201620 sept. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for renal neuromodulation via catheters having expandable treatment members
US945686914 mars 20164 oct. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for bilateral renal neuromodulation
US946306222 juil. 201111 oct. 2016Boston Scientific Scimed, Inc.Cooled conductive balloon RF catheter for renal nerve ablation
US94630668 oct. 201511 oct. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for renal neuromodulation
US946848729 avr. 201318 oct. 2016Tsunami Medtech, LlcMedical instrument and method of use
US946849714 mars 201618 oct. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for monopolar renal neuromodulation
US947456316 avr. 201425 oct. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods for renal neuromodulation
US94862703 août 20158 nov. 2016Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for bilateral renal neuromodulation
US94863557 janv. 20138 nov. 2016Vessix Vascular, Inc.Selective accumulation of energy with or without knowledge of tissue topography
US949862420 nov. 201422 nov. 2016Nephera Ltd.Stimulation of the urinary system
US95109017 nov. 20126 déc. 2016Vessix Vascular, Inc.Selectable eccentric remodeling and/or ablation
US952682730 avr. 201427 déc. 2016Ablative Solutions, Inc.Peri-vascular tissue ablation catheter with support structures
US95390474 nov. 201510 janv. 2017Ablative Solutions, Inc.Transvascular methods of treating extravascular tissue
US955484914 mai 201531 janv. 2017Ablative Solutions, Inc.Transvascular method of treating hypertension
US956135211 mars 20107 févr. 2017Delpor, Inc.Implantable device for long-term delivery of drugs
US957903020 juil. 201228 févr. 2017Boston Scientific Scimed, Inc.Percutaneous devices and methods to visualize, target and ablate nerves
US959238621 déc. 201214 mars 2017Vessix Vascular, Inc.Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US961039819 nov. 20124 avr. 2017Incube Labs, LlcImplantable solid-liquid drug delivery apparatus, formulations, and methods of use
US961587517 mars 201411 avr. 2017Tsunami Med Tech, LLCMedical instruments and techniques for thermally-mediated therapies
US962967519 oct. 201225 avr. 2017Confluent Medical Technologies, Inc.Tissue treatment device and related methods
US96361743 mars 20162 mai 2017Medtronic Ardian Luxembourg S.A.R.L.Methods for therapeutic renal neuromodulation
US964915327 oct. 201016 mai 2017Holaira, Inc.Delivery devices with coolable energy emitting assemblies
US964915414 nov. 201416 mai 2017Holaira, Inc.Non-invasive and minimally invasive denervation methods and systems for performing the same
US964915612 févr. 201516 mai 2017Boston Scientific Scimed, Inc.Bipolar off-wall electrode device for renal nerve ablation
US966880922 août 20126 juin 2017Holaira, Inc.Systems, assemblies, and methods for treating a bronchial tree
US966881123 sept. 20116 juin 2017Boston Scientific Scimed, Inc.Minimally invasive access for renal nerve ablation
US967541231 oct. 201413 juin 2017Holaira, Inc.Delivery devices with coolable energy emitting assemblies
US96754139 févr. 201613 juin 2017Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for renal neuromodulation
US968716610 oct. 201427 juin 2017Boston Scientific Scimed, Inc.High resolution cardiac mapping electrode array catheter
US969382128 févr. 20144 juil. 2017Boston Scientific Scimed, Inc.Medical devices for modulating nerves
US970037219 nov. 201211 juil. 2017Recor Medical, Inc.Intraluminal methods of ablating nerve tissue
US970703423 mai 201218 juil. 2017Recor Medical, Inc.Intraluminal method and apparatus for ablating nerve tissue
US97070358 août 201618 juil. 2017Medtronic Ardian Luxembourg S.A.R.L.Methods for catheter-based renal neuromodulation
US970703625 juin 201418 juil. 2017Boston Scientific Scimed, Inc.Devices and methods for nerve modulation using localized indifferent electrodes
US97134836 mars 201425 juil. 2017Medtronic Vascular, Inc.Catheters and related devices for forming passageways between blood vessels or other anatomical structures
US97137304 oct. 201225 juil. 2017Boston Scientific Scimed, Inc.Apparatus and method for treatment of in-stent restenosis
US971792114 mars 20141 août 2017Micron Devices, LLCTreating inflammation, chronic pain and other disorders with neuromodulation
US97311321 sept. 201615 août 2017Medtronic Ardian Luxembourg S.A.R.L.Methods for renal neuromodulation
US974398314 mars 201629 août 2017Medtronic Ardian Luxembourg S.A.R.L.Renal neuromodulation for treatment of patients
US975719217 mars 201612 sept. 2017Medtronic Ardian Luxembourg S.A.R.L.Renal neuromodulation for treatment of patients
US975719328 avr. 201612 sept. 2017Medtronic Ardian Luxembourg S.A.R.L.Balloon catheter apparatus for renal neuromodulation
US97571966 janv. 201612 sept. 2017Angiodynamics, Inc.Multiple treatment zone ablation probe
US977060613 oct. 201426 sept. 2017Boston Scientific Scimed, Inc.Ultrasound ablation catheter with cooling infusion and centering basket
US979544131 juil. 201524 oct. 2017Ablative Solutions, Inc.Methods of ablating tissue using a catheter injection system
US980830019 févr. 20137 nov. 2017Boston Scientific Scimed, Inc.Control of arterial smooth muscle tone
US98083114 mars 20147 nov. 2017Boston Scientific Scimed, Inc.Deflectable medical devices
US981487319 sept. 201614 nov. 2017Medtronic Ardian Luxembourg S.A.R.L.Methods and apparatus for bilateral renal neuromodulation
US20060212078 *6 mars 200621 sept. 2006Ardian, Inc.Methods and apparatus for treating congestive heart failure
US20070265687 *24 juil. 200715 nov. 2007Ardian, Inc.Apparatuses for renal neuromodulation
US20090036948 *6 août 20085 févr. 2009Ardian, Inc.Renal nerve stimulation methods for treatment of patients
US20090062873 *26 juin 20085 mars 2009Ardian, Inc.Methods and systems for thermally-induced renal neuromodulation
US20090076409 *28 juin 200719 mars 2009Ardian, Inc.Methods and systems for thermally-induced renal neuromodulation
US20100010567 *25 sept. 200914 janv. 2010The Foundry, LlcSystems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US20100114244 *31 oct. 20086 mai 2010Medtronic, Inc.Electrical renal autonomic blockade
US20100114254 *31 oct. 20086 mai 2010Medtronic, Inc.Subclavian ansae stimulation
US20100119792 *10 nov. 200813 mai 2010Zheng-Dong MaThree-dimensional auxetic structures and applications thereof
US20100137860 *11 août 20093 juin 2010Ardian, Inc.Apparatus for performing a non-continuous circumferential treatment of a body lumen
US20100168731 *21 août 20091 juil. 2010Ardian, Inc.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100168739 *30 juin 20091 juil. 2010Ardian, Inc.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100222851 *11 mai 20102 sept. 2010Ardian, Inc.Methods for monitoring renal neuromodulation
US20100222854 *11 mai 20102 sept. 2010Ardian, Inc.Apparatuses for inhibiting renal nerve activity via an intra-to-extravascular approach
US20100268307 *30 juin 201021 oct. 2010Ardian,Inc.Methods for intravascularly-induced neuromodulation
US20110106006 *11 mars 20105 mai 2011Martin Francis JImplantable device for long-term delivery of drugs
US20110112400 *5 nov. 201012 mai 2011Ardian, Inc.High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation
US20110166499 *7 mars 20117 juil. 2011Ardian, Inc.Methods and apparatus for inducing controlled renal neuromodulation
US20110200171 *19 janv. 201118 août 2011Ardian, Inc.Methods and apparatus for renal neuromodulation via stereotactic radiotherapy
US20110202098 *14 janv. 201118 août 2011Ardian, Inc.Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US20150100040 *8 oct. 20149 avr. 2015Terumo Kabushiki KaishaMedical material supply device
EP2626024A3 *14 août 200918 déc. 2013Ardian, Inc.Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
EP3005986A1 *9 oct. 200913 avr. 2016Kirk Promotion LTD.Infusion of drugs
EP3135237A1 *15 mars 20131 mars 2017Covidien LPEnergy delivery device
WO2010105093A211 mars 201016 sept. 2010Delpor, Inc.Implantable device for long-term delivery of drugs
WO2010105093A3 *11 mars 201024 mars 2011Delpor, Inc.Implantable device for long-term delivery of drugs
WO2013038013A117 sept. 201221 mars 2013Syntach AgA device, and a method for treatment of increased blood pressure
WO2013078257A2 *20 nov. 201230 mai 2013Incube Labs, IncImplantable solid-liquig drug delivery apparatus, formulations, and methods of use
WO2013078257A3 *20 nov. 20121 août 2013Incube Labs, IncImplantable solid-liquig drug delivery apparatus, formulations, and methods of use
WO2013134667A1 *8 mars 201312 sept. 2013Mayo Foundation For Medical Education And ResearchModulating afferent signals to treat medical conditions
WO2013169741A1 *7 mai 201314 nov. 2013Stein Emily AAgents and devices for affecting nerve function
WO2014153223A1 *14 mars 201425 sept. 2014Perryman Laura TylerTreating inflammation, chronic pain and other disorders with neuromodulation
Classifications
Classification aux États-Unis424/422, 604/523, 607/3, 604/20
Classification internationaleA61F2/00, A61N1/02, A61M5/00, A61N1/36, A61N1/362, A61N1/32
Classification coopérativeA61M2205/05, A61M2205/50, A61K9/0004, A61M5/145, A61K45/06, A61K31/529, A61K31/52, A61K31/135, A61L29/146, A61K9/0012, A61M2005/14513, A61K9/7007, A61N1/36007, A61N1/36114, A61M2210/1082, A61N1/3627, A61N1/0551, A61M5/14276, A61M5/1723, A61N1/326, A61N1/36117
Classification européenneA61M5/142P10, A61N1/36Z, A61M5/172B, A61N1/36Z3J, A61N1/32, A61N1/32P, A61N1/36
Événements juridiques
DateCodeÉvénementDescription
29 juin 2010ASAssignment
Owner name: FOUNDRY NEWCO 8, INC.,CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:G&L CONSULTING, LLC;REEL/FRAME:024611/0120
Effective date: 20041117
Owner name: ARDIAN, INC.,CALIFORNIA
Free format text: CHANGE OF NAME;ASSIGNOR:FOUNDRY NEWCO 8, INC.;REEL/FRAME:024611/0132
Effective date: 20050118
Owner name: G&L CONSULTING, LLC,NEW YORK
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GELFAND, MARK;LEVIN, HOWARD R.;REEL/FRAME:024612/0796
Effective date: 20041116
Owner name: FOUNDRY NEWCO 8, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:G&L CONSULTING, LLC;REEL/FRAME:024611/0120
Effective date: 20041117
Owner name: ARDIAN, INC., CALIFORNIA
Free format text: CHANGE OF NAME;ASSIGNOR:FOUNDRY NEWCO 8, INC.;REEL/FRAME:024611/0132
Effective date: 20050118
Owner name: G&L CONSULTING, LLC, NEW YORK
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GELFAND, MARK;LEVIN, HOWARD R.;REEL/FRAME:024612/0796
Effective date: 20041116